Cytotoxic and Genotoxic Effects of Waterpipe on Oral Health Status

Systematic review and meta-analysis

*Ricardo Grillo,1 Mehdi Khemiss,2 Yuri S. da Silva3

ABSTRACT: This systematic review and meta-analysis aimed to assess the cytotoxic and genotoxic impacts of waterpipe smoking on oral health. The databases MEDLINE, Cochrane Library and Dimensions were searched to find studies evaluating whether waterpipe smokers exhibited any cytotoxic or genotoxic effects on their oral cells compared to non-smokers, with regard to mouth neoplasms. Particularly, changes in DNA methylation and p53 expression were assessed. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were adopted for the systematic review. Review Manager was utilised for statistical analysis with a significance level at P < 0.05. To assess the grades of the included articles, a risk of bias analysis was summarised. A forest plot, including some of the included articles included, was created regarding the different grades. A total of 20 studies were included in this review. The results showed that waterpipe smoking has cytotoxic and genotoxic effects on oral cells, with a risk difference of 0.16. Although the published articles are few in number, all confirm the devastating effects of waterpipe smoking related to the carcinogenicity. Waterpipe smoking is harmful to oral health. It causes a series of detrimental cellular and genetic modifications such as acanthosis, epithelial dysplasia and hyperparakeratosis. In addition, waterpipe smoking increases the incidence of oral cancer.

Keywords: Mouth Neoplasms; Oral Health; Smoking Waterpipes; Tobacco Use; Toxicity Tests.

OBACCO IS SMOKED IN MANY DIFFERENT WAYS. Waterpipe smoking is one form of tobacco use that has gained popularity in the past decades. In this light, a systematic review conducted in 2018 showed that the prevalence of waterpipe use was alarmingly high in the Eastern Mediterranean and European regions, especially among the youth.¹

Waterpipe smoke contains a variety of carcinogens such as naphthylamines, tobacco-specific nitrosamines, polycyclic aromatic hydrocarbons, primary aromatic amines, along with carbon monoxide carbonyls (such as formaldehyde, acetaldehyde or acrolein).² Moreover, waterpipe use for smoking is associated with DNA damage and cell death; these kinds of genotoxicity and cytotoxicity are also involved in oral carcinogenesis.3 Indeed, laboratorybased investigations on waterpipe smoking showed various genomic and transcriptomic alterations previously observed in various types of cancer.⁴ In fact, Walters et al. observed concomitant changes in DNA methylation at 727 locations in the genome.5 Thus, DNA methylation may predispose cells to cancer (by activating specific genes and repressing others) and it also plays a significant role in metastasis.^{6,7} In addition, nuclear changes in the oral mucosa cells of waterpipe smokers (WS) were previously reported.8 These changes occur in the early stages of cancer and may be used as biomarkers to screen oral dysplastic and malignant lesions.⁹

However, the contribution of waterpipe use to the development of oral cancer is not adequately established.² Furthermore, the few available studies on this topic do not explicitly focus on oral cancers.¹⁰ With regard to addressing this knowledge gap, this study aimed to systematically review the scientific literature regarding the cytotoxic or genotoxic effects of waterpipe smoking on oral mucosal cells.¹¹

Methods

The systematic review and meta-analysis were conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.¹² This study protocol was registered in the PROSPERO database (CRD42021238867).

Only original studies regarding the cytotoxicity and genotoxicity of waterpipe use were considered in the systematic review. Additionally, the following inclusion criteria were considered: (1) studies on regular waterpipe users; (2) studies demonstrating cytotoxic or genotoxic effects of waterpipe smoking; and (3) studies that included comparisons with a control group.

¹Department of Oral and Maxillofacial Surgery, Faculdade São Leopoldo Mandic, Campinas, Brazil; ²Department of Dental Medicine, Fattouma Bourguiba University Hospital, University of Monastir, Monastir, Tunisia; ³Department of Oral & Maxillofacial Surgery, UniFG University Center, Guanambi, Brazil *Corresponding Author's e-mail: doutorgrillo@uol.com.br

This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

This study's search was conducted online by two researchers (RG and MK) in MEDLINE (via PubMed), Cochrane Library, Health Virtual Library (BVS) and Dimensions, with no date restriction until December 2021. The terms chosen in the primary articles selected to justify this review were combined with Boolean operators (OR/AND) within the population, intervention, control and outcome (PICO) framework. Here, the following strategy was used: ([hookah] OR [shisha] OR [waterpipe] OR ["waterpipe"] OR [narghile]) AND ([oral] OR [oral health] OR [dental] OR [buccal]) NOT (systematic review). As per the PICO framework, the following questions were to be answered: Do waterpipe smokers (P) demonstrate any cytotoxic or genotoxic effects on oral cells (I) compared to non-smokers (C) regarding mouth neoplasms (O)?

The exclusion criteria were as follows: (1) studies with clinical changes; (2) studies with radiographic modifications; (3) studies performed on the head, face and neck; and (4) animal studies. Moreover, comparative studies without conclusions specific to waterpipe toxicity were excluded. In addition, studies that met the inclusion criteria or those with doubtful information either in their titles or abstracts were selected for full-text assessments in this review's second round.

Two researchers (RG and MK) independently extracted the following data from the included studies for analysis: year of study, demographic data, cytotoxic and/or genotoxic effects, waterpipe use and control group sizes. Any discrepancies were resolved by arriving at a consensus. In the case of persisting discrepancies, arbitration was performed by a third researcher (YSS). Notably, alterations related to micronuclei, pyknosis, karyorrhexis and karyolysis were discussed.

To assess the quality of the studies, their risk of bias was assessed according to the Quality Assessment Tool for Diagnosis Accuracy Studies (QUADAS-2).¹³ The data obtained using this tool were used in the Review Manager Software 5.4 (Review Manager (RevMan), Version 5.4 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration). The concomitant results were considered as statistically significant with a 95% confidence interval.

The QUADAS-2 Tool assessed the risks of bias and applicability across the selected studies to evaluate the following aspects: (1) patient selection: description of patient selection and inclusion; (2) index text: description of the index test, its conduction and interpretation; (3) reference standard: description of the reference standard, its conduction and interpretation; and (4) flow and timing of each included article: description of patients who did not receive the index test or reference standard and who were excluded.

Results

The first bibliographic search found 346 records from the previously mentioned databases; however, BVS returned no results. Thereafter, duplicate studies were excluded, leading to a remainder of 181 articles. After screening and excluding papers that were unrelated to the study topic, 38 robust studies remained relevant. Then, reports from the same authors/coauthors or the same study centre were excluded, (e.g. reviews, comments, letters, hypotheses and expert opinions).^{3,14–26} Additionally, two exclusively microbiological studies were removed, and two were considered as animal studies.^{27–30} However, one study was found but could not be retrieved properly.³¹ Furthermore, manual search retrieved no additional papers [Figure 1].

The full-text of all studies viewed from the first round were independently checked to ensure each reviewer's eligibility. Finally, a total of 20 articles were included in this review. The selected articles included information on authors, year of publication, demographic data, cytotoxic or genotoxic evaluation and the number of patients in the waterpipe and control groups [Table 1].

Three studies were conducted in vitro,^{4,32,33} while biological samples were obtained from patients in 17 studies.^{8,31,33–37,39–48} In addition, the levels of pro-inflammatory cytokines, receptor activator of nuclear factor- κ B (RANKL) and osteoprotegerin were evaluated.^{34–36}

Six studies were found to have investigated the genotoxic effect of waterpipe smoke.^{4,32,33,37-39} A comet assay was performed in one of these




Figure 1: Flow diagram of included articles.

Author and year of publication	City (country)	Cytotoxic/genotoxic	Waterpipe group	Control group
Ali ⁴⁶ (2007)	NM (Yemen)	Cytotoxic	11	11
El-Setouhy et al. ⁸ (2008)	Cairo (Egypt)	Genotoxic	128	78
Al-Amrah <i>et al</i> . ³³ (2014)	Jeddah (Saudi Arabia)	Genotoxic	20	0
Seifi <i>et al.</i> ⁴⁵ (2014)	Babol (Iran)	Cytotoxic	40	40
Eker <i>et al.</i> ⁴⁰ (2016)	Mersin (Turkey)	Genotoxic	30	30
Naderi and Pasha ⁴³ (2017)	Tehran (Iran)	Cytotoxic	25	25
Volkova <i>et al.</i> ⁴² (2017)	Krakiv (Ukraine)	Cytotoxic	13	38
Abduljabbar <i>et al.</i> ³⁵ (2018)	Riyadh (Saudi Arabia)	Cytotoxic	41	44
Alharbi <i>et al.</i> ⁴⁷ (2018)	Jazan (Saudi Arabia)	Cytotoxic	70	140
AlQahtani <i>et al.</i> ³⁴ (2018)	Riyadh (Saudi Arabia)	Cytotoxic	40	40
Mokeem <i>et al.</i> ³⁶ (2018)	Riyadh (Saudi Arabia)	Cytotoxic	40	38
Silveira <i>et al.</i> ⁴⁴ (2018)	Cascavel (Brazil)	Genotoxic	40	40
Zaid <i>et al.</i> ⁴⁸ (2018)	Syria (Lebanon)	Cytotoxic	52	53
Amer <i>et al.</i> ⁴⁹ (2019)	Cairo (Egypt)	Cytotoxic	16	16
Patil <i>et al.</i> ⁴ (2019)	Multicentre*	Genotoxic	-	-
Prasad <i>et al.</i> ⁴¹ (2019)	Ajman (United Arab Emirates)	Genotoxic	100	100
Taghibakhsh <i>et al.</i> ³⁹ (2019)	Tehran (Iran)	Cytotoxic	36	36
López-Ozuna <i>et al</i> . ³² (2020)	Multicentre*	Genotoxic	-	_
Rajabi-Moghaddam <i>et al.</i> ³⁸ (2020)	Birjand (Iran)	Genotoxic	30	30
Sabi <i>et al.</i> ³⁷ (2020)	Irbid (Jordan)	Genotoxic	150	150

Tal	ole	e 1:	Incl	ludeo	l stuc	lies	in c	hrono	logical	orc	ler ^{4,8,32–49}
-----	-----	------	------	-------	--------	------	------	-------	---------	-----	--------------------------

*The study was conducted on human cell lines.

studies.³³ Cell-line models were used to understand the mechanisms of action of waterpipe smoke on oral cells.^{4,32} In the study by Patil et al., immortalised non-transformed normal (human) oral keratinocytes (OKF6/TERT1) chronically (i.e. for eight months) exposed to waterpipe smoke were developed.4 When the phenotypic alterations were studied, they revealed genomic anomalies in OKF6/TERT1-waterpipe cells, with some overexpressed and some downregulated genes. In another study that developed a cell-line model, two normal (human) oral epithelial cells were treated with 100 g/L of waterpipe smoke solution for two days.32 Upon examination, it was observed that both cells became more elongated and showed decreased cell-cell contact compared to the untreated cells. This epithelial-mesenchymal transition was also accompanied by the deregulation of a set of genes related to oncogenesis.32

On the other hand, eight studies evaluated the nuclear changes in cytology samples from the buccal mucosa of patients.^{8,38–40,41,43–45} In these studies, some pathological assessments were performed, including micronuclei (DNA aggregates separating from the primary nucleus), karyorrhexis (nuclear fragmentation), karyolysis (complete dissolution of nuclear components), pyknosis (shrinkage or condensation of a cell), acanthosis (benign abnormal thickening of the stratum spinosum), hyperparakeratosis (abnormal keratinisation of the epidermal stratum coreum), and epithelial dysplasia (architectural and cytological epithelial changes).

The mean of micronuclei, cell nucleus perimeter, and area was found to be contrasting in the WS group compared to the non-smoker (NS) group.^{8,38–42} In addition, the mean percentages of karyorrhexis, karyolysis and pyknosis showed substantial changes.^{43–45} Other histopathologic changes such as acanthosis, hyperparakeratosis and epithelial dysplasia were found to be associated with waterpipe use. Therefore, an increased incidence of oral cancer was related to different types of tobacco use.^{46,47}

Moreover, waterpipe smoke was associated with changes in DNA methylation.³⁷ In fact, approximately 64% of global DNA methylation was detected in DNA samples isolated from the WS group compared to the NS group. In addition, promoter methylation of the *MLH1* gene was observed in the oral epithelium of the WS group.³⁷

The mutations of tumour suppressor protein p53 were also found to be associated with waterpipe

Events Total Events Total 1.1 micronuclei ere at $d^{(1)}(2016)$ 6 30 4 30 52 0.07 (-012, 0.25) -Setoudy et al. ⁽¹⁾ (2008) 10 68 4 22 53 -0.03 (-0.22, 0.15) saad et at. ⁽¹⁾ (2019) 10 36 5 55 55 2.014 (-0.05, 0.32) inbitoal (95% CI) 264 218 29.0 0.09 (0.04, 0.15) inbitoal (95% CI) 26 6 6 12.3 0.09 (-0.01, 0.15) ider and Pault ⁽²⁾ (217) 3 25 1 25 6 10.08 (-0.07, 0.23) breat act al. ⁽²⁾ (2018) 7 40 3 40 6.2 0.09 (-0.01, 0.19) tal events 10 4 12 40 48 0.05 (-0.15, 0.15) tad events 10 4 10 12 40 48 0.05 (-0.15, 0.15) tad events 10 10 10 10 15 0.05 (-0.15, 0.15) tad events 10	Study or subgroup	Experimental		Control		Weight in %	Risk difference (95% CI)	Risk difference M-H, Random, 95% CI	
The start of the		Events	Total	Events	Total	111 /0	())/()())		
Secondly et al. ⁶ (2008) 10 68 4 22 53 - 0.03 (0.22, 0.15) asad et al. ⁶ (2019) 1 00 2 100 78 0.10 (0.03, 0.17) asad et al. ⁶ (2019) 7 30 2 30 54 0.17 (-0.01, 0.34) asad et al. ⁶ (2019) 10 36 5 36 5.2 0.14 (-0.05, 0.32) bitotal (95% CI) 2 64 2 218 29.0 0.09 (0.04, 0.15) bitotal (95% CI) 2 64 2 218 29.0 0.09 (0.04, 0.15) bitotal (95% CI) 3 25 1 25 61 0.08 (-0.07, 0.23) detria at al. ⁶ (2018) 7 40 3 40 6.2 0.10 (-0.04, 0.24) bitotal (95% CI) 6 5 6 6 12.3 0.09 (-0.01, 0.19) bitotal (95% CI) 7 4 25 1 25 5.7 0.12 (-0.04, 0.28) bitotal (95% CI) 6 5 6 6 12.3 0.09 (-0.01, 0.19) bitotal (95% CI) 7 4 25 1 25 5.7 0.12 (-0.04, 0.28) bitotal (95% CI) 6 5 6 6 12.3 0.05 (-0.15, 0.25) bitotal (95% CI) 6 5 6 6 11.0 0.05 (-0.15, 0.25) bitotal (95% CI) 6 5 6 6 11.0 0.09 (-0.03, 0.21) bitotal (95% CI) 6 5 6 6 11.0 0.09 (-0.03, 0.21) bitotal (95% CI) 6 5 6 6 11.0 0.09 (-0.03, 0.21) bitotal (95% CI) 6 5 6 6 11.0 0.09 (-0.03, 0.21) bitotal (95% CI) 6 5 6 6 11.0 0.09 (-0.03, 0.21) bitotal (95% CI) 6 5 6 6 11.0 0.09 (-0.03, 0.21) bitotal (95% CI) 6 5 6 6 11.0 0.09 (-0.03, 0.21) bitotal (95% CI) 6 5 6 6 11.0 0.09 (-0.03, 0.21) bitotal (95% CI) 8 1 8 4 10.6 0.45 (0.05, 0.35) bitotal (95% CI) 8 1 8 4 10.6 0.45 (0.05, 0.35) bitotal (95% CI) 8 1 8 4 10.6 0.45 (0.05, 0.81) bitotal (95% CI) 8 1 8 4 10.6 0.45 (0.05, 0.81) bitotal (95% CI) 8 1 8 4 10.6 0.45 (0.05, 0.81) bitotal (95% CI) 8 1 8 4 9.8 0.31 (0.10, 0.52) bitotal (95% CI) 8 1 8 4 9.8 0.31 (0.10, 0.52) bitotal (95% CI) 8 1 8 4 9.8 0.31 (0.10, 0.52) bitotal (95% CI) 8 1 8 4 9.8 0.31 (0.10, 0.52) bitotal (95% CI) 8 1 8 4 9.8 0.31 (0.10, 0.52) bitotal (95% CI) 8 1 8 4 9.8 0.31 (0.10, 0.52) bitotal (95% CI) 7 742 705 100.0 0.16 (0.09, 0.23) bitotal (95% CI) 7 742 705 100.0 0.16 (0.09, 0.23) bitotal (95% CI) 7 742 705 100.0 0.16 (0.09, 0.23) bitotal (95% CI) 7 742 705 100.0 0.16 (0.09, 0.23) bitotal (95% CI) 7 742 705 100.0 0.16 (0.09, 0.23) bitotal (95% CI) 7 742 705 100.0 0.16 (0.09, 0.23) bitotal (95% CI) 7 742 705 100.0 0.16 (0.09, 0.23) bi	1.1.1 micronuclei								
asad <i>e</i> $d^{12}(2019)$ 12 100 2 100 7.8 0.10 (0.03, 0.17) asad <i>e</i> $d^{12}(2019)$ 7 30 2 30 5.4 0.17 (-0.10, 0.34) asad <i>e</i> $d^{12}(2019)$ 7 30 2 30 5.4 0.17 (-0.10, 0.34) asad <i>e</i> $d^{12}(2019)$ 10 36 5 3.6 5.2 0.14 (-0.05, 0.32) bitotal (95% CI) 264 218 29.0 0.09 (0.04, 0.15) 1.2 pyknosis aderi and Pasha ⁴² (2017) 3 2.5 1 2.5 6.1 0.08 (-0.07, 0.23) aderi and Pasha ⁴² (2017) 3 2.5 1 2.5 6.1 0.08 (-0.07, 0.23) aderi and Pasha ⁴² (2017) 3 2.5 1 2.5 6.1 0.08 (-0.07, 0.23) bitotal (95% CI) 10 65 4.6 0.23 0.09 (-0.04, 0.28) bitotal (95% CI) 12 4.2 5 1 2.5 5.7 0.12 (-0.04, 0.28) aderi and Pasha ⁴² (2017) 4 2.5 1 2.5 5.7 0.12 (-0.04, 0.28) aderi and Pasha ⁴² (2017) 4 2.5 1 2.5 5.7 0.12 (-0.04, 0.28) aderi and Pasha ⁴² (2017) 4 2.5 1 0.5 10.5 10.5 10.5 10.5 10.5 10.5 1	Eker <i>et al.</i> ⁴⁰ (2016)	6		4			0.07 (-0.12, 0.25)		
and et al. ¹⁰ (2019) 7 30 2 30 54 0.17 (-0.01, 0.34) and et al. ¹⁰ (2019) 10 36 53 6 53 5 20 0.14 (-0.05, 0.32) bitotal (95% CI) 264 218 29.0 0.09 (0.04, 0.15) bitotal (95% CI) 254 7 - 20.4, df - 4 (P - 0.57); F - 0% st for overall effect: Z - 3.36 (P - 0.0008) 1.2 pyknosis aderi and Pasha ⁴ (2017) 3 25 1 25 61 0.08 (-0.07, 0.23) bitotal (95% CI) 65 65 65 12.3 0.09 (-0.01, 0.19) bitotal (95% CI) 65 65 65 12.3 0.09 (-0.01, 0.19) bitotal (95% CI) 7 40 3 40 6.2 0.10 (-0.04, 0.24) bitotal (95% CI) 7 4 25 1 25 57 012 (-0.04, 0.28) bitotal (95% CI) 8 40 10 40 43 9 005 (-0.15, 0.25) bitotal (95% CI) 8 40 10 40 44 9 0.15 (-0.05, 0.35) bitotal (95% CI) 8 40 10 40 44 9 0.15 (-0.05, 0.35) bitotal (95% CI) 8 40 10 40 44 9 0.15 (-0.05, 0.35) bitotal (95% CI) 8 40 10 40 44 9 0.15 (-0.05, 0.35) bitotal (95% CI) 8 40 10 40 44 45 0.005 (-0.13, 0.23) bitotal (95% CI) 6 65 65 11.0 0.09 (-0.03, 0.21) bitotal (95% CI) 6 65 65 11.0 0.09 (-0.03, 0.21) bitotal (95% CI) 7 4 25 1 25 57 0.12 (-0.04, 0.28) bitotal (95% CI) 6 40 10 40 8 40 53 0.005 (-0.13, 0.23) bitotal (95% CI) 6 41 6 44 4.8 0.27 (0.07, 0.48) [Qathani et al. ¹⁶ (2018) 26 41 16 44 4.8 0.27 (0.07, 0.48) [Qathani et al. ¹⁶ (2018) 26 41 16 44 4.8 0.457 (0.07, 0.48) [Qathani et al. ¹⁶ (2018) 26 41 16 44 4.8 0.457 (0.07, 0.48) [Qathani et al. ¹⁶ (2018) 26 41 16 44 4.8 0.457 (0.07, 0.48) [Qathani et al. ¹⁶ (2018) 26 41 16 44 4.8 0.27 (0.07, 0.48) [Qathani et al. ¹⁶ (2018) 26 41 16 44 4.8 0.27 (0.07, 0.48) [Qathani et al. ¹⁶ (2018) 26 41 16 44 4.8 0.27 (0.07, 0.48) [Qathani et al. ¹⁶ (2018) 30 41 14 44 5.1 0.41 (0.22, 0.61) [Qathani et al. ¹⁶ (2018) 30 41 14 44 5.1 0.41 (0.22, 0.61) [Qathani et al. ¹⁶ (2018) 30 41 14 44 5.1 0.41 (0.22, 0.61) [Qathani et al. ¹⁶ (2018) 30 41 14 44 5.1 0.41 (0.22, 0.61) [Qathani et al. ¹⁶ (2018) 30 41 14 44 5.1 0.41 (0.22, 0.61) [Qathani et al. ¹⁶ (2018) 10 40 1 40 6.2 0.23 (0.08, 0.37) bitotal (95% CI) 81 84 19.8 0.31 (0.10, 0.52) bitotal (95% CI) 72 12 7.00 100 0.16 (0.09, 0.23) bitotal (95% C								-	
sade $ta^{1/2}(2019)$ 10 36 5 36 5.2 0.14 (-0.05, 0.32) bioloal (95% CI) 264 218 29.0 0.09 (0.04, 0.15) tal events 45 17 eterogenetity: Tau" = 0.00; Chi" = 20.4, df = 4 (P = 0.57); F = 0% st for overall effect: Z = 3.36 (P = 0.0008) L2 pyknosis aderi and Pasha" (2017) 3 25 1 25 6.1 0.08 (-0.07, 0.23) twist at d. ¹⁰ (2018) 7 40 3 40 6.2 0.10 (-0.04, 0.24) tal events 10 4 4 terogenetity: Tau" = 0.00; Chi" = 0.00, df = 1 (P = 0.055); F = 0% st for overall effect: Z = 1.72 (P = 0.09) L3 kayyorrhesis aderi and Pasha" (2017) 4 25 1 25 5.7 0.12 (-0.04, 0.28) thif et al. ¹⁰ (2018) 16 40 10 40 49 0.15 (-0.05, 0.35) thif et al. ¹⁰ (2018) 10 40 40 40 0.15 (-0.5, 0.35) thif et al. ¹⁰ (2018) 10 40 19 0.0 (-0.025); F = 0% st for overall effect: Z = 1.38 (P = 0.05); F = 0% st for overall effect: Z = 1.38 (P = 0.05); F = 0% st for overall effect: Z = 1.38 (P = 0.05); F = 0% st for overall effect: Z = 1.38 (P = 0.05); F = 0% st for overall effect: Z = 1.31 (P = 0.05); F = 0% st for overall effect: Z = 1.31 (P = 0.05); F = 0% st for overall effect: Z = 1.31 (P = 0.05); F = 0% st for overall effect: Z = 1.31 (P = 0.05); F = 0% st for overall effect: Z = 1.31 (P = 0.05); F = 0% st for overall effect: Z = 1.31 (P = 0.06); F = 5% st for overall effect: Z = 1.31 (P = 0.00); F = 5% st for overall effect: Z = 2.91 (P = 0.001); F = 5% st for overall effect: Z = 2.91 (P = 0.001); F = 5% st for overall effect: Z = 2.91 (P = 0.001); F = 5% st for overall effect: Z = 2.91 (P = 0.001); F = 5% st for overall effect: Z = 2.94 (P = 0.002); F = 13% st for overall effect: Z = 2.94 (P = 0.003); F = 0.5% st for overall effect: Z = 2.94 (P = 0.003); F = 0.95 tal events 20 7 tal events 20 7 tal events 226 104 eterogenetity: Tau" = 0.00; Chi" = 1.14 (d = 1.14 P = 0.29); F = 1.3% st for overall effect: Z = 2.94 (P = 0.003); F = 0.95 tal events 226 104 eterogenetity: Tau" = 0.01; Chi" = 54.99, df = 1.74 (P = 0.00001); F = 69% st for overall effect: Z = 2.94 (P = 0.0001); F = 69% st for overall effect: Z = 2									
biotal 99% C1) ' 264' 218' 29.0 0.09 (0.04, 0.15) tracerogeneity: Tar ² - 0.05, Ch ² - 2.94, df - 4 (P - 0.57); F = 0% st for overall effect: 2 - 3.36 (P - 0.0008) L2 pyknoss: ader: and Pasha ⁴ (2017) 3 25 1 25 61 0.08 (-0.07, 0.23) who and Pasha ⁴ (2017) 3 25 1 2.35 0.09 (-0.01, 0.19) tal events: ader: and Pasha ⁴ (2017) 4 25 1 2.5 57 0.12 (-0.04, 0.28) who and Pasha ⁴ (2017) 4 25 1 2.5 57 0.12 (-0.04, 0.28) the at alt ⁴ (2018) 16 40 10 40 4.9 0.015 (-0.05, 0.25) the at alt ⁴ (2018) 16 40 10 40 4.9 0.015 (-0.05, 0.25) the at alt ⁴ (2018) 16 40 10 40 4.9 0.015 (-0.05, 0.25) the at alt ⁴ (2018) 16 40 10 40 4.9 0.015 (-0.05, 0.25) the at alt ⁴ (2018) 16 40 10 40 4.9 0.015 (-0.05, 0.25) the at alt ⁴ (2018) 16 40 10 40 8.4 0.53 0.005 (-0.13, 0.23) tal events 3 34 23 eccorgeneity: Tar ² - 0.00; Ch ² - 0.50 df - 2 (P - 0.78); F - 0% st for overall effect: Z - 1.98 (P - 0.05) 1.1 karyophysis ader: and Pasha ⁴ (2017) 4 25 1 25 57 0.12 (-0.04, 0.28) the at alt ⁴ (2018) 10 40 8 40 5.3 0.05 (-0.13, 0.23) tal events 14 9 eccorgeneity: Tar ² - 0.00; Ch ² - 0.53, df - 1 (P - 0.55); F - 0% st for overall effect: Z - 1.38 (P - 0.15) 1.1 Laryophysis ader: and Pasha ⁴ (2017) 4 25 1 25 5.7 0.12 (-0.04, 0.28) the at alt ⁴ (2018) 10 40 8 40 5.3 0.05 (-0.13, 0.23) tal events 14 9 eccorgeneity: Tar ² - 0.00; Ch ² - 0.57, df - 1 (P - 0.05); F = 0% st for overall effect: Z - 1.43 (P - 0.15) 1.5 IL-1 biduilable at alt ⁶ (2018) 26 41 16 44 4.8 0.27 (0.07, 0.48) (Qabtani et al. ⁸ (2018) 26 41 16 44 4.8 0.53 (0.04, 0.05) tal events 53 18 eccorgeneity: Tar ² - 0.05; Ch ¹ - 7.07, df - 1 (P - 0.000; I ¹ = 87% st for overall effect: Z - 2.91 (P - 0.004) 1.5 IL-6 biduilable at alt ⁸ (2018) 20 40 12 40 4.7 0.20 (-0.01, 0.41) (Addition et al. ⁸ (2018) 20 40 12 40 4.7 0.20 (-0.01, 0.41) (Dattani et al. ⁸ (2018) 20 40 12 40 4.7 0.20 (-0.01, 0.41) (Dattani et al. ⁸ (2018) 10 41 6 44 57 0.111 (-0.06, 0.27) (Dattani et al. ⁸ (2018) 10 40 1 40 6.2 0.23 (0.08, 0.37) tal (+	
tal events $1 = 42$, 234 , $41 = 4(P - 0.57)$; $P = 0\%$ st for overall effect: $Z = 3.36$ ($P = 0.0008$) 12 pyknosis aderi and Psaha ⁶¹ (2017) 3 25 1 25 6.1 0.08 ($-0.07, 0.23$) theria <i>et al.</i> ⁴² (2018) 7 40 3 40 6.2 0.10 ($-0.04, 0.24$) bytotal (95% CD) 65 66 12.3 0.09 ($-0.01, 0.19$) aderi and Psaha ⁶² (2017) 4 25 1 25 5.7 0.12 ($-0.04, 0.28$) theria <i>et al.</i> ⁴² (2018) 16 40 10 40 40 9 0.15 ($-0.05, 0.52$) bytotal (95% CD) 16 10 15 4 0.11 ($0.000, 0.22$) theria <i>et al.</i> ⁴² (2018) 16 40 10 40 40 9 0.15 ($-0.05, 0.52$) theria <i>et al.</i> ⁴² (2018) 16 40 105 105 15.4 0.11 ($0.000, 0.22$) theria <i>et al.</i> ⁴² (2018) 10 40 8 40 3.3 0.05 ($-0.13, 0.23$) bytotal (95% CD) 65 66 11.0 0.09 ($-0.03, 0.21$) thetal events 34 23 eterogenetity: Tat ² = 0.00; Ch ² = 0.50; H = 0.55; H = 0% st for overall effect: $Z = 1.88$ ($P = 0.55$); H = 0% st for overall effect: $Z = 1.81$ ($P = 0.55$); H = 0% st for overall effect: $Z = 1.48$ ($P = 0.55$); H = 0% st for overall effect: $Z = 1.48$ ($P = 0.55$); H = 0% st for overall effect: $Z = 1.48$ ($P = 0.55$); H = 0% st for overall effect: $Z = 1.48$ ($P = 0.55$); H = 0% st for overall effect: $Z = 1.48$ ($P = 0.55$); H = 0% st for overall effect: $Z = 1.48$ ($P = 0.15$) 1.5 IL-1 bytotal (95% CD) 65 61 10 0.09 ($-0.03, 0.21$) thotal (95% CD) 81 84 9.8 0.31 ($0.10, 0.52$) the eterogenetity: Tat ² = 0.01; Ch ² = 1.70; di = 1 ($P = 0.106$); H = 87% st for overall effect: $Z = 2.94$ ($P = 0.001$) 1.5 IL-6 bytotal (95% CD) 81 84 9.8 0.31 ($0.10, 0.52$) the eterogenetity: Tat ² = 0.01; Ch ² = 7.70; di = 1 ($P = 0.29$); F = 13% st for overall effect: $Z = 2.94$ ($P = 0.003$) 1.5 -0.5 0 0.5 Non-smokers waterplipe		10		5				•	
terogeneity: $\operatorname{Tat}^{2} - 0.00, \operatorname{Ch}^{2} - 2.94, df - 4(P - 0.57); F - 0\%$ stor overall effect: $Z = 3.36 (P - 0.0008)$ 1.2 pyknosis ader: and Pasha ⁴¹ (2017) 3 2.5 1 2.5 6.1 0.08 (-0.07, 0.23) there is at $d^{18}(2018)$ 7 40 3 40 6.2 0.10 (-0.04, 0.24) bitotal (95% CI) 6 65 65 12.3 0.09 (-0.01, 0.19) tal events 10 4 40 12 40 4.8 0.05 (-0.15, 0.25) there at $d^{18}(2018)$ 16 40 10 40 49 0.15 (-0.05, 0.35) there at $d^{18}(2017)$ 4 25 1 25 5.7 0.12 (-0.04, 0.28) there at $d^{18}(2018)$ 16 40 10 40 49 0.15 (-0.05, 0.35) there at $d^{18}(2018)$ 16 40 10 40 49 0.15 (-0.05, 0.35) there at $d^{18}(2018)$ 16 40 10 5 10.5 15.4 0.11 (0.00, 0.22) tal events 3 34 23 eterogeneity: $\operatorname{Tat}^{2} - 0.00, \operatorname{Ch}^{2} - 0.50, df = 2 (P = 0.78); P = 0\%$ st for overall effect: $Z = 1.98 (P = 0.05)$ 1.1 $\operatorname{Karyophysis}$ ader: and Pasha ⁴¹ (2017) 4 25 1 25 5.7 0.12 (-0.04, 0.28) there at $d^{18}(2018)$ 10 40 8 40 5.3 0.05 (-0.13, 0.23) bitotal (95% CI) 65 65 11.0 0.09 (-0.03, 0.21) tal events 14 9 eterogeneity: $\operatorname{Tat}^{2} - 0.00, \operatorname{Ch}^{2} - 0.25); F = 0\%$ st for overall effect: $Z = 1.48 (P = 0.15)$ 1.5 $\operatorname{II-1}$ bitotal (95% CI) 81 84 10.6 0.45 (0.09, 0.81) tal events 53 18 eterogeneity: $\operatorname{Tat}^{2} - 0.05; \operatorname{Ch}^{2} - 1 (P = 0.55); F = 0\%$ st for overall effect: $Z = 2.46 (P = 0.01)$ 1.5 $\operatorname{II-1}$ bitotal (95% CI) 81 84 9.8 0.31 (0.10, 0.52) tal events 53 18 eterogeneity: $\operatorname{Tat}^{2} - 0.01; \operatorname{Ch}^{2} - 2.15, df = 1 (P = 0.19); F = 5\%$ st for overall effect: $Z = 2.94 (P = 0.004)$ 1.7 TNF bitotal (95% CI) 742 705 100.0 0.16 (0.09, 0.23) tal events 20 77 tal events 20 77 st for overall effect: $Z = -2.94 (P = 0.003)$ 5.1 $(-9, 0.05, \operatorname{Ch}^{2} - 1.72 (P = 0.29); F = 1.3\%$ st for overall effect: $Z = -2.94 (P = 0.003)$ 5.1 $(-9, 0.05, \operatorname{Ch}^{2} - 1.72 (P = 0.00001)$ 5.2 $\operatorname{II-1} = 0.05, \operatorname{Ch}^{2} - 1.72 (P = 0.00001)$ 5.2 $\operatorname{II-1} = 0.05, \operatorname{Ch}^{2} - 1.72 (P = 0.00001)$ 5.2 $\operatorname{II-1} = 0.05, \operatorname{Ch}^{2} - 1.72 (P = 0.00001)$ 5.2 $\operatorname{II-1} = 0.05, \operatorname{Ch}^{2} - 1.72 (P = 0.00001)$ 5.2 $$	()	45	204	17	210	29.0	0.09 (0.04, 0.15)		
st for overall effect: Z = 3.36 ($P = 0.0008$) 1.2 pyknosis aderi and Psaha ⁴¹ (2017) 3 25 1 25 6.1 0.08 ($+0.07, 0.23$) twins <i>et al.</i> ⁴² (2018) 7 40 3 40 62 0.09 ($+0.01, 0.19$) twins <i>et al.</i> ⁴² (2018) 7 40 4. df = 1 ($P = 0.35$); $P = 0\%$ st for overall effect: Z = 1.72 ($P = 0.009$) 1.3 kayourhexis aderi and Psaha ⁴⁰ (2017) 4 25 1 25 5.7 0.12 ($+0.04, 0.28$) thif <i>et al.</i> ⁴⁴ (2018) 16 40 10 40 49 0.15 ($+0.05, 0.25$) thif <i>et al.</i> ⁴⁴ (2018) 16 40 10 40 49 0.15 ($+0.05, 0.25$) thir <i>et al.</i> ⁴⁴ (2018) 10 40 8 40 5.3 0.05 ($+0.05, 0.23$) thir <i>et al.</i> ⁴⁴ (2018) 10 40 8 40 5.3 0.05 ($+0.03, 0.21$) thera <i>et al.</i> ⁴⁴ (2018) 10 40 8 40 5.3 0.05 ($+0.03, 0.21$) thera <i>et al.</i> ⁴⁴ (2018) 10 40 8 40 5.3 0.05 ($+0.03, 0.21$) thera <i>et al.</i> ⁴⁴ (2018) 10 40 8 40 5.3 0.05 ($+0.03, 0.21$) thera <i>et al.</i> ⁴⁴ (2018) 10 40 8 40 5.3 0.05 ($+0.03, 0.21$) thera <i>et al.</i> ⁴⁴ (2018) 10 40 8 40 5.3 0.05 ($+0.03, 0.21$) thera <i>et al.</i> ⁴⁴ (2018) 10 40 8 40 5.3 0.05 ($+0.03, 0.21$) thera <i>et al.</i> ⁴⁴ (2018) 10 40 8 40 5.3 0.05 ($+0.03, 0.21$) thera <i>et al.</i> ⁴⁴ (2018) 10 40 8 40 5.3 0.05 ($+0.03, 0.21$) thera <i>et al.</i> ⁴⁴ (2018) 22 41 ($P = 0.05$); $P = 0\%$ st for overall effect: $Z = 1.43$ ($P = 0.05$) d $= 1.69$ 4.4 5.1 0.41 ($0.22, 0.61$) (Datababer <i>et al.</i> ³⁵ (2018) 20 40 12 40 4.7 0.20 ($+0.00, 0.81$) that events 5 3 18 84 10.6 0.45 ($0.09, 0.81$) that events 5 50 70 26 terogenety: Taa' $= 0.00$; $Ch^2 = -2.21$, $de = 1 (P = 0.006$); $P = 8.7\%$ st for overall effect: $Z = 2.91 (P = 0.004$) 1.5 TNF biobiol (95% CI) 7 742 705 100.0 0.16 ($0.09, 0.23$) tal events 20 77 742 705 100.0 0.16 ($0.09, 0.23$) tal events 20 77 742 705 100.0 0.16 ($0.09, 0.23$) tal events 20 77 742 705 100.0 0.16 ($0.09, 0.23$) tal events 226 104 eterogenety: Taa' $= 0.01$; $Ch^2 = 54.99$, $d = 1.7 (P = 0.0000); P = 69\%st for overall effect: Z = 4.64 (C = 1.7) (P = 0.29); P = 1.3\%st for overall effect: Z = 4.66 (-6 (P = 0.09); P = 0.07\%$			= 4 (P =		0%				
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	0 /		· · · · ·	0.07 // 1	070				
before et d^{14} (2018) T 40 + 34 + 40 + 12 + 40 + 5.1 + 0.10 (-0.04, 0.24) tal events 10 4 eterogeneity: Tau ² = 0.004, df = 1 (P = 0.85); F = 0% est for overall effect: Z = 1.72 (P = 0.09) L3 kayyor hexis aderi and Pasha ⁴ (2017) 4 25 1 25 5.7 0.12 (-0.04, 0.28) the etrogeneity: Tau ² = 0.00; Ch ² = 0.50, df = 2 (P = 0.78); F = 0% est for overall effect: Z = 1.98 (P = 0.05) L4 karyolysis aderi and Pasha ⁴ (2017) 4 25 1 25 5.7 0.12 (-0.04, 0.28) the etrogeneity: Tau ² = 0.00; Ch ² = 0.50, df = 2 (P = 0.78); F = 0% est for overall effect: Z = 1.98 (P = 0.05) L4 karyolysis aderi and Pasha ⁴ (2017) 4 25 1 25 5.7 0.12 (-0.04, 0.28) the etrogeneity: Tau ² = 0.00; Ch ² = 0.53, df = 1 (P = 0.55); F = 0% est for overall effect: Z = 1.43 (P = 0.15) L5 IL-1 bduijabbar et al. ²⁸ (2018) 26 41 16 44 4.88 0.27 (0.07, 0.48) (Qahtari et al. ²⁸ (2018) 26 41 16 44 4.88 0.63 (0.16, 0.79) tal events 53 48 10.6 0.45 (0.09, 0.81) tal events 53 18 eterogeneity: Tau ² = 0.06; Ch ² = 7.70, df = 1 (P = 0.066; I ² = 87% est for overall effect: Z = 2.46 (P = 0.01) L6 IL-6 bduijabbar et al. ²⁸ (2018) 30 41 14 44 5.1 0.41 (0.22, 0.61) (Qahtari et al. ²⁸ (2018) 30 41 14 44 5.1 0.41 (0.22, 0.61) Qahtari et al. ²⁸ (2018) 30 41 14 44 5.1 0.41 (0.22, 0.61) (Qahtari et al. ²⁸ (2018) 30 41 14 44 5.1 0.41 (0.22, 0.61) (Qahtari et al. ²⁸ (2018) 30 41 14 44 5.1 0.41 (0.22, 0.61) (Qahtari et al. ²⁸ (2018) 30 41 14 44 5.1 0.41 (0.22, 0.61) (Qahtari et al. ²⁸ (2018) 10 40 12 40 4.7 0.201 (-0.01, 0.41) thotal (95% Ch) 81 84 9.8 0.31 (0.10, 0.52) tal events 50 26 eterogeneity: Tau ² = 0.00; Chi ² = .16, df = 1 (P = 0.14); I ² = 54% est for overall effect: Z = .2.91 (P = 0.000) L6 IL-6 bduijabbar et al. ²⁸ (2018) 10 40 14 06 62 0.23 (0.08, 0.27) tal events 226 104 tal even	1.1.2 pyknosis								
biotal (95% C1) 65 65 12.3 0.09 (-0.01, 0.19) tal events 10 4 terrogeneity: Tau ² = 0.00; Chi ² = 0.04, df = 1 ($P = 0.85$); $\Gamma = 0\%$ set for overall effect: $Z = 1.72 (P = 0.09)$ 1.3 kayyorrhexis aderi and Pasha ⁴ (2017) 4 25 1 25 5.7 0.12 (-0.04, 0.28) thif et di ⁵ (2014) 14 40 12 40 4.8 0.05 (-0.15, 0.25) biotal (95% C1) 105 105 15.4 0.11 (0.00, 0.22) tal events 34 23 terrogeneity: Tau ² = 0.00; Chi ² = 0.50, df = 2 ($P = 0.78$); $\Gamma = 0\%$ set for overall effect: $Z = 1.98 (P = 0.05)$ 1.4 karyolysis aderi and Pasha ⁴ (2017) 4 25 1 25 5.7 0.12 (-0.04, 0.28) thetrai et di ⁴ (2018) 10 40 8 40 5.3 0.05 (-0.13, 0.23) thetrai et di ⁴ (2018) 10 40 8 40 5.3 0.05 (-0.13, 0.23) thetrai et di ⁴ (2018) 10 40 8 40 5.3 0.05 (-0.13, 0.23) thetrai et di ⁴ (2018) 10 40 8 40 5.3 0.05 (-0.13, 0.23) thetrai et di ⁴ (2018) 27 40 2 40 5.8 0.63 (0.46, 0.79) thetrai et di ⁴ (2018) 27 40 2 40 5.8 0.63 (0.46, 0.79) thotal (95% C1) 81 84 10.6 0.45 (0.09, 0.81) tal events 53 18 terogeneity: Tau ² = 0.00; Chi ² = 7.70, df = 1 ($P = 0.006$); $\Gamma = 87\%$ set for overall effect: $Z = 2.46 (P = 0.01)$ L6 II-6 biduljabbar et al. ³⁸ (2018) 30 41 14 44 5.1 0.41 (0.22, 0.61) Qahtani et al. ⁴⁸ (2018) 20 40 12 40 4.7 0.20 (-0.01, 0.41) tal events 50 26 terogeneity: Tau ² = 0.00; Chi ² = 2.16, df = 1 ($P = 0.14$); $\Gamma = 57\%$ set for overall effect: $Z = 2.91 (P = 0.004)$ L7 TNF biduljabbar et al. ⁴⁸ (2018) 10 41 6 44 5.7 0.11 (-0.06, 0.27) (botal (95% C1) 81 84 119 0.17 (0.06, 0.27) tal events 20 7 7 terogeneity: Tau ² = 0.00; Chi ² = 1.14, df = 1 ($P = 0.29$); $\Gamma = 13\%$ set for overall effect: $Z = 2.94 (P = 0.000)$ tal events 20 7 terogeneity: Tau ² = 0.00; Chi ² = 1.44, df = 1 ($P = 0.29$); $\Gamma = 30.7\%$ set for overall effect: $Z = 2.46 (P = 0.000)$ tal events 226 104 terogeneity: Tau ² = 0.00; Chi ² = 1.44, df = 1 ($P = 0.29$); $\Gamma = 30.7\%$ set for overall effect: $Z = 4.64 - 6 (P = 0.019)$; $\Gamma = 30.7\%$	Naderi and Pasha ⁴³ (2017)		25		25	6.1	0.08 (-0.07, 0.23)		
tal events 0 0 0 Åt ² 0 0 Å df = 1 ($P = 0.85$); $I^2 = 0\%$ st for overall effect: $Z = 1.72$ ($P = 0.09$) 1.3 kayorrhexis adder and Pasha ⁴⁴ (2017) 4 25 1 25 5.7 0.12 (-0.04, 0.28) affer at 45 (2014) 14 40 12 40 48 0.05 (-0.15, 0.25) theta de ⁴⁵ (2014) 16 40 10 40 49 0.15 (-0.05, 0.035) theta de ⁴⁵ (2013) 16 40 10 40 49 0.15 (-0.05, 0.035) that events 3 42 23 tal events 3 42 23 tal events 3 42 23 tal events 42 (2018) 10 40 8 40 5.3 0.05 (-0.13, 0.28) theta de ⁴⁵ (2018) 10 40 8 40 5.3 0.05 (-0.13, 0.23) theta de ⁴⁵ (2018) 10 40 8 40 5.3 0.05 (-0.13, 0.23) theta de ⁴⁵ (2018) 10 40 8 40 5.3 0.05 (-0.13, 0.23) tal events 14 9 terogeneity: Tau ² = 0.00; Ch ² = 0.35, df = 1 ($P = 0.55$); $I^2 = 0\%$ st for overall effect: $Z = 1.43$ ($P = 0.15$) 1.5 H -1 biolar (95% CI) 65 65 11.0 0.09 (-0.03, 0.21) tal events 14 9 terogeneity: Tau ² = 0.06; Ch ² = 7.70, df = 1 ($P = 0.55$); $I^2 = 0\%$ st for overall effect: $Z = 1.43$ ($P = 0.15$) 1.5 H -1 biolar (95% CI) 81 84 10.6 0.45 (0.09, 0.81) tal events 53 18 18 st for overall effect: $Z = 1.40$ ($P = 0.00\%$); $I^2 = 87\%$ st for overall effect: $Z = 2.46$ ($P = 0.01$) 1.6 H -6 bidliplabar et al. ¹⁸ (2018) 30 41 14 44 5.1 0.41 (0.22, 0.61) (Qahtarit et al. ¹⁸ (2018) 30 41 14 44 5.1 0.41 (0.22, 0.61) (Qahtarit et al. ¹⁸ (2018) 30 41 14 44 5.1 0.41 (0.22, 0.61) (Qahtarit et al. ¹⁸ (2018) 30 41 14 44 5.1 0.41 (0.22, 0.61) (Qahtarit et al. ¹⁸ (2018) 30 41 14 64 5.7 0.11 (-0.06, 0.27) tal events 50 26 terogeneity: Tau ³ = 0.00; Chi ² = 1.16, df = 1 ($P = 0.14$); $I^2 = 54\%$ st for overall effect: $Z = 2.49$ ($P = 0.000$) 1.6 (DA⁴) 77 2 705 100.0 0.16 (0.09, 0.23) tal events 20 7 tal events 226 104 terogeneity: Tau ² = 0.01; Chi ² = 54.99; df = 17 ($P = 0.00001$); $I^2 = 69\%$ st for overall effect: $Z = -2.94$ ($P = 0.00001$) 1.6 (DA⁴) 95% CI) 772 705 100.0 0.16 (0.09, 0.23) tal events 226 104 terogeneity: Tau ² = 0.01; Chi ² = 54.99; df = 17 ($P = 0.00001$); $I^2 = 69\%$ st for overall effect:	Silveira <i>et al.</i> ⁴⁴ (2018)	7		3			0.10 (-0.04, 0.24)	•	
terogeneity: Tau ² = 0.00; Chi ² = 0.04; df = 1 ($P = 0.85$); l ² = 0% st for overall effect: Z = 1.72 ($P = 0.09$) L3 kayyorrhexis aderi and Pasha ⁴ (2017) 4 25 1 25 5.7 0.12 (-0.04, 0.28) thif et al. ⁶² (2018) 16 4 0 10 40 4.9 0.05 (-0.15, 0.25) bitotal (95% Cl) 105 15.4 0.11 (0.00, 0.22) that events 34 23 terogeneity: Tau ² = 0.00; Chi ² = 0.5, df = 2 ($P = 0.78$); l ² = 0% st for overall effect: Z = 1.98 ($P = 0.05$) L4 karyolysis aderi and Pasha ⁴⁰ (2017) 4 25 1 25 5.7 0.12 (-0.04, 0.28) bitotal (95% Cl) 65 65 11.0 0.09 (-0.03, 0.21) that events 49 53 0.05 (-0.13, 0.23) bitotal (95% Cl) 16 5 65 11.0 0.09 (-0.03, 0.21) that events 14 9 st for overall effect: Z = 1.43 ($P = 0.15$) L5 L-1 bitotal (95% Cl) 81 84 10.6 0.45 (0.09, 0.81) tal events 53 18 terogeneity: Tau ² = 0.06; Chi ² = 7.70, df = 1 ($P = 0.006$); l ² = 87% st for overall effect: Z = 2.46 ($P = 0.01$) L6 L-6 biduljabbar et al. ³⁶ (2018) 20 40 12 40 4.7 0.20 (-0.01, 0.41) bitotal (95% Cl) 81 84 9.8 0.31 (0.10, 0.52) tal events 53 18 terogeneity: Tau ² = 0.00; Chi ² = 2.16, df = 1 ($P = 0.14$); l ² = 54% st for overall effect: Z = 2.91 ($P = 0.004$) L7 TNF biduljabbar et al. ³⁶ (2018) 10 41 6 44 5.7 0.11 (-0.06, 0.27) (Qahtari et al. ³⁶ (2018) 10 41 6 44 5.7 0.11 (-0.06, 0.27) bidul (95% Cl) 81 84 11.9 0.17 (0.06, 0.29) tal events 20 7 terogeneity: Tau ² = 0.00; Chi ² = 1.14, df = 1 ($P = 0.29$); l ² = 13% st for overall effect: Z = 2.91 ($P = 0.003$) tal events 20 7 terogeneity: Tau ² = 0.00; Chi ² = 1.14, df = 1 ($P = 0.29$); l ² = 13% st for overall effect: Z = 2.94 ($P = 0.003$) tal events 20 7 terogeneity: Tau ² = 0.00; Chi ² = 1.14, df = 1 ($P = 0.29$); l ² = 13% st for overall effect: Z = 2.94 ($P = 0.003$) tal events 20 7 terogeneity: Tau ² = 0.00; Chi ² = 1.14, df = 1 ($P = 0.29$); l ² = 13% st for overall effect: Z = 4.66 ($P = 0.003$) tal events 20 7 terogeneity: Tau ² = 0.00; Chi ² = 1.14, df = 1 ($P = 0.29$); l ² = 1.6% st for overall effect: Z = 4.66 ($P $			65		65	12.3	0.09 (-0.01, 0.19)	•	
st for overall effect: $Z = 1.72 (P = 0.09)$ L3 kayyorrhexis aderi and Pasha ⁴ (2017) 4 25 1 25 5.7 0.12 (-0.04, 0.28) ifi et al. ⁴² (2018) 16 40 10 40 4.9 0.15 (-0.05, 0.35) ibitotal (95% Ct) 105 105.4 0.11 (0.00, 0.22) eterogeneity: Tau ² = 0.00; Ch ² = 0.50, df = 2 (P = 0.78); l ² = 0% st for overall effect: $Z = 1.98 (P = 0.05)$ L4 karyophysis aderi and Pasha ⁴⁰ (2017) 4 25 1 25 5.7 0.12 (-0.04, 0.28) ibitotal (95% Ct) 65 df = 1 (P = 0.55); l ² = 0% st for overall effect: $Z = 1.43 (P = 0.15)$ L5 IL-1 bduljabbar et al. ⁴⁴ (2018) 26 41 16 44 4.8 0.27 (0.07, 0.48) [Qahtani et al. ⁴⁴ (2018) 27 40 2 40 5.8 0.63 (0.46, 0.79) ibitotal (95% Ct) 81 84 10.6 0.45 (0.09, 0.81) ital events 53 18 eterogeneity: Tau ² = 0.06; Chi ² = 7.70, df = 1 (P = 0.06); l ² = 87% st for overall effect: $Z = 2.46 (P = 0.01)$ L6 IL-6 bduljabbar et al. ⁴⁴ (2018) 30 41 14 44 5.1 0.41 (0.22, 0.61) [Qahtani et al. ⁴⁴ (2018) 20 40 12 40 4.7 0.20 (-0.01, 0.41) btotal (95% Ct) 81 84 9.8 0.31 (0.10, 0.52) ital events 50 26 eterogeneity: Tau ² = 0.01; Chi ² = 2.16, df = 1 (P = 0.14); l ² = 54% st for overall effect: $Z = 2.91 (P = 0.004)$ L7 TNF bduljabbar et al. ⁴⁴ (2018) 10 41 6 44 5.7 0.11 (-0.06, 0.27) [Qahtani et al. ⁴⁴ (2018) 10 41 6 44 5.7 0.11 (-0.06, 0.27) [Qahtani et al. ⁴⁴ (2018) 10 40 1 40 6.2 0.23 (0.08, 0.37) ital events 20 7 eterogeneity: Tau ² = 0.00; Chi ² = 1.14, df = 1 (P = 0.29); l ² = 13% st for overall effect: $Z = 2.94 (P = 0.0003)$ ital events 20 7 eterogeneity: Tau ² = 0.00; Chi ² = 1.14, df = 1 (P = 0.29); l ² = 13% st for overall effect: $Z = 2.94 (P = 0.0003)$ ital events 20 7 eterogeneity: Tau ² = 0.00; Chi ² = 1.14, df = 1 (P = 0.29); l ² = 13% st for overall effect: $Z = 2.94 (P = 0.0003)$ ital events 20 7 ital events 226 (104 ital events 226 (104 ital events 226 (104 ital events 200 7 ital events 226 (104 ital events 200 7 ital events 200 7 ital events 200 Chi ² = 1.19; l ² (102; l ² = 69% st for overall effect: Z = 4.60 (P = 0.0003)	Fotal events Hotorogonoity: Tau ² – 0.00: Ch		_ 1 (D_	-	0%				
aderi and Pasha ⁴² (2017) 4 25 1 25 5.7 0.12 (-0.04, 0.28) if et al. ⁴² (2018) 16 40 10 40 4.9 0.15 (-0.05, 0.35) biotal (95% CI) 105 105 15.4 0.11 (0.00, 0.22) val events at al. ⁴⁴ (2018) 16 40 40 4.9 0.15 (-0.05, 0.35) biotal (95% CI) 105 105 15.4 0.11 (0.00, 0.22) val events and Pasha ⁴² (2017) 4 25 1 25 5.7 0.12 (-0.04, 0.28) veira et al. ⁴⁴ (2018) 10 40 8 40 5.3 0.05 (-0.13, 0.23) biotal (95% CI) 65 65 11.0 0.09 (-0.03, 0.21) val events 14 9 everogeneity: Tau ² = 0.00; Chi ² = 0.35, df = 1 (P = 0.55); l ² = 0% st for overall effect: Z = 1.43 (P = 0.15) L5 IL-1 biotal (95% CI) 65 65 11.0 0.09 (-0.03, 0.21) val events 14 9 cerosgeneity: Tau ² = 0.06; Chi ² = 7.70, df = 1 (P = 0.55); l ² = 0% st for overall effect: Z = 2.46 (P = 0.15) L5 IL-1 biotal (95% CI) 81 84 10.6 0.45 (0.09, 0.81) val events 33 18 eterogeneity: Tau ² = 0.06; Chi ² = 7.70, df = 1 (P = 0.006); l ² = 87% st for overall effect: Z = 2.46 (P = 0.01) L6 IL-6 bidujabbar et al. ³⁶ (2018) 30 41 14 44 5.1 0.41 (0.22, 0.61) idq lefter: Z = 2.46 (P = 0.01) L6 IL-6 bidujabbar et al. ³⁶ (2018) 30 41 14 44 5.1 0.41 (0.22, 0.61) idq lefter: Z = 2.91 (P = 0.004) L7 TNF biotal (95% CI) 81 84 9.8 0.31 (0.10, 0.52) val events 20 7 idq lefter: Z = 2.91 (P = 0.003) tal events 20 7 tetrogeneity: Tau ² = 0.00; Chi ² = 1.14, df = 1 (P = 0.14); l ² = 54% st for overall effect: Z = 2.94 (P = 0.003) tal events 226 104 tetrogeneity: Tau ² = 0.00; Chi ² = 1.44, df = 1 (P = 0.29); l ² = 13% st for overall effect: Z = 2.94 (P = 0.003) tal events 226 104 tal events 226 104 tetrogeneity: Tau ² = 0.00; Chi ² = 1.17 (P = 0.29); l ² = 13% st for overall effect: Z = 2.94 (P = 0.003) tal events 226 104 tetrogeneity: Tau ² = 0.00; Chi ² = 1.44, df = 1 (P = 0.29); l ² = 30.7% tal events 200 7 tal events 226 104 tetrogeneity: Tau ² = 0.00; Chi ² = 1.49, df = 17 (P = 0.09); l ² = 30.7% tal events 200 7 tal events 200 7 tal events 226 104 tetrogeneity: Tau ² = 0.01; Chi ² = 4.94, gf = 17 (P = 0.0000			- 1 (1 -	0.03),1 -	070				
aderi and Pasha ⁴² (2017) 4 25 1 25 5.7 0.12 (-0.04, 0.28) if et al. ⁴² (2018) 16 40 10 40 4.9 0.15 (-0.05, 0.35) biotal (95% CI) 105 105 15.4 0.11 (0.00, 0.22) val events at al. ⁴⁴ (2018) 16 40 40 4.9 0.15 (-0.05, 0.35) biotal (95% CI) 105 105 15.4 0.11 (0.00, 0.22) val events and Pasha ⁴² (2017) 4 25 1 25 5.7 0.12 (-0.04, 0.28) veira et al. ⁴⁴ (2018) 10 40 8 40 5.3 0.05 (-0.13, 0.23) biotal (95% CI) 65 65 11.0 0.09 (-0.03, 0.21) val events 14 9 everogeneity: Tau ² = 0.00; Chi ² = 0.35, df = 1 (P = 0.55); l ² = 0% st for overall effect: Z = 1.43 (P = 0.15) L5 IL-1 biotal (95% CI) 65 65 11.0 0.09 (-0.03, 0.21) val events 14 9 cerosgeneity: Tau ² = 0.06; Chi ² = 7.70, df = 1 (P = 0.55); l ² = 0% st for overall effect: Z = 2.46 (P = 0.15) L5 IL-1 biotal (95% CI) 81 84 10.6 0.45 (0.09, 0.81) val events 33 18 eterogeneity: Tau ² = 0.06; Chi ² = 7.70, df = 1 (P = 0.006); l ² = 87% st for overall effect: Z = 2.46 (P = 0.01) L6 IL-6 bidujabbar et al. ³⁶ (2018) 30 41 14 44 5.1 0.41 (0.22, 0.61) idq lefter: Z = 2.46 (P = 0.01) L6 IL-6 bidujabbar et al. ³⁶ (2018) 30 41 14 44 5.1 0.41 (0.22, 0.61) idq lefter: Z = 2.91 (P = 0.004) L7 TNF biotal (95% CI) 81 84 9.8 0.31 (0.10, 0.52) val events 20 7 idq lefter: Z = 2.91 (P = 0.003) tal events 20 7 tetrogeneity: Tau ² = 0.00; Chi ² = 1.14, df = 1 (P = 0.14); l ² = 54% st for overall effect: Z = 2.94 (P = 0.003) tal events 226 104 tetrogeneity: Tau ² = 0.00; Chi ² = 1.44, df = 1 (P = 0.29); l ² = 13% st for overall effect: Z = 2.94 (P = 0.003) tal events 226 104 tal events 226 104 tetrogeneity: Tau ² = 0.00; Chi ² = 1.17 (P = 0.29); l ² = 13% st for overall effect: Z = 2.94 (P = 0.003) tal events 226 104 tetrogeneity: Tau ² = 0.00; Chi ² = 1.44, df = 1 (P = 0.29); l ² = 30.7% tal events 200 7 tal events 226 104 tetrogeneity: Tau ² = 0.00; Chi ² = 1.49, df = 17 (P = 0.09); l ² = 30.7% tal events 200 7 tal events 200 7 tal events 226 104 tetrogeneity: Tau ² = 0.01; Chi ² = 4.94, gf = 17 (P = 0.0000	1.1.3 kayyorrhexis								
liveine tal^{14} (2018) 16 40 10 40 49 0.15 (-0.05, 0.35) biotal (95% CI) 34 23 tetrogenicity: Tau ² = 0.00; Chi ² = 0.50; df = 2 (P = 0.78); F = 0% stof or overall effect: Z = 1.98 (P = 0.05) 1.4 karyolysis aderi and Pasha ⁴² (2017) 4 25 1 25 5.7 0.12 (-0.04, 0.28) liveira $et al^{14}$ (2018) 10 40 8 40 5.3 0.05 (-0.13, 0.23) biotal (95% CI) 165 65 11.0 0.09 (-0.03, 0.21) stal events 14 (2018) 26 41 16 44 4.8 0.27 (0.07, 0.48) IQahtani et al^{14} (2018) 27 40 2 40 5.8 0.63 (0.46, 0.79) biotal (95% CI) 53 18 tetrogeneity: Tau ² = 0.06; Chi ² = 7.70, df = 1 (P = 0.056); F = 0% st for overall effect: Z = 2.46 (P = 0.01) 1.6 IL-6 biduljabbar et al^{14} (2018) 20 40 12 40 4.7 0.20 (-0.01, 0.41) biotal (95% CI) 58 1 84 9.8 0.31 (0.10, 0.52) tal events 23 18 tetrogeneity: Tau ² = 0.01; Chi ² = 2.16, df = 1 (P = 0.14); F = 54% st for overall effect: Z = 2.91 (P = 0.004) 1.7 TNF tetrogeneity: Tau ² = 0.00; Chi ² = 1.14, df = 1 (P = 0.14); F = 54% st for overall effect: Z = 2.94 (P = 0.003) tal events 20 7 tetrogeneity: Tau ² = 0.00; Chi ² = 1.44, df = 1 (P = 0.29); F = 13% st for overall effect: Z = 2.94 (P = 0.003) tal events 20 7 tetrogeneity: Tau ² = 0.00; Chi ² = 1.14, df = 1 (P = 0.29); F = 13% st for overall effect: Z = 2.94 (P = 0.003) tal events 20 7 tetrogeneity: Tau ² = 0.00; Chi ² = 1.14, df = 1 (P = 0.29); F = 13% st for overall effect: Z = 2.94 (P = 0.003) tal events 226 104 tetrogeneity: Tau ² = 0.00; Chi ² = 1.14, df = 1 (P = 0.29); F = 30.7% tal events 226 0.5 Non-smokers waterpipe	Naderi and Pasha ⁴³ (2017)	4	25	1	25	5.7	0.12 (-0.04, 0.28)	-	
biotal (95% CI) 105 105 15.4 0.11 (0.00, 0.22) tal events 34 23 terrogeniety: Tau ² = 0.00; Ch ² = 0.50, df = 2 ($P = 0.78$); l ² = 0% st for overall effect: $Z = 1.98$ ($P = 0.05$) 1.4 karyolysis aderi and Pasha ⁴³ (2017) 4 25 1 25 5.7 0.12 (-0.04, 0.28) liveira <i>et al.</i> ⁴⁴ (2018) 10 40 8 40 5.3 0.05 (-0.13, 0.23) biotal (95% CI) 65 65 11.0 0.09 (-0.03, 0.21) abtotal (95% CI) 65 65 11.0 0.09 (-0.03, 0.21) 1.5 IL-1 biduljabbar <i>et al.</i> ³⁵ (2018) 26 41 16 44 4.8 0.27 (0.07, 0.48) (Qahtani <i>et al.</i> ³⁵ (2018) 27 40 2 40 5.8 0.63 (0.46, 0.79) bital events 53 18 terrogeneity: Tau ² = 0.06; Ch ² = 7.70, df = 1 ($P = 0.006$); l ² = 87% st for overall effect: $Z = 2.46$ ($P = 0.01$) 1.6 IL-6 biduljabbar <i>et al.</i> ³⁵ (2018) 30 41 14 44 5.1 0.41 (0.22, 0.61) Qahtani <i>et al.</i> ³⁵ (2018) 30 41 12 40 4.7 0.20 (-0.01, 0.41) bital events 50 26 terogeneity: Tau ² = 0.01; Ch ² = 2.16, df = 1 ($P = 0.14$); l ² = 54% st for overall effect: $Z = 2.91$ ($P = 0.004$) 1.7 TNF biduljabbar <i>et al.</i> ³⁵ (2018) 10 41 6 44 5.7 0.11 (-0.06, 0.27) Qahtani <i>et al.</i> ³⁵ (2018) 10 40 1 40 6.2 0.23 (0.08, 0.37) bitotal (95% CI) 81 84 119 0.17 (0.06, 0.29) stal events 20 7 terogeneity: Tau ² = 0.00; Ch ² = 1.14, df = 1 ($P = 0.29$); l ² = 1.3% st for overall effect: $Z = 2.94$ ($P = 0.03$) tal events 20 7 terogeneity: Tau ² = 0.01; Ch ² = 54.99, df = 17 ($P = 0.29$); l ² = 1.3% st for overall effect: $Z = 2.94$ ($P = 0.03$) tal events 226 104 terogeneity: Tau ² = 0.01; Ch ² = 54.99, df = 17 ($P = 0.29$); l ² = 1.3% st for overall effect: $Z = 2.94$ ($P = 0.003$) tal events 226 104 terogeneity: Tau ² = 0.01; Ch ² = 54.99, df = 17 ($P = 0.290$); l ² = 69% stal for overall effect: $Z = 4.66$ ($P = 0.0001$) tal events 226 104 terogeneity: Tau ² = 0.01; Ch ² = 54.99, df = 17 ($P = 0.290$); l ² = 69% stal for overall effect: $Z = 4.66$ ($P = 0.0001$) tal events 226 104 tal events 226	Seifi et al.45 (2014)	14	40	12		4.8			
tal events 34 23 eterogeniety: Tau ² = 0.00; Ch ² = 0.50, df = 2 (P = 0.78); l ² = 0% st for overall effect: Z = 1.98 (P = 0.05) 14 karyolysis aderi and Pasha ⁴⁵ (2017) 4 25 1 25 5.7 0.12 (-0.04, 0.28) liveira <i>et al.</i> ⁴⁴ (2018) 10 40 8 40 5.3 0.05 (-0.13, 0.23) bivotal (95% CI) 1 65 65 11.0 0.09 (-0.03, 0.21) tal events 14 9 9 eterogeneity: Tau ² = 0.00; Ch ² = 0.35, df = 1 (P = 0.55); l ² = 0% st for overall effect: Z = 1.43 (P = 0.15) 1.5 IL-1 biduljabbar <i>et al.</i> ³⁵ (2018) 26 41 116 44 4.8 0.27 (0.07, 0.48) [Qahtani <i>et al.</i> ³⁴ (2018) 27 40 2 40 5.8 0.63 (0.46, 0.79) bitotal (95% CI) 81 84 10.6 0.45 (0.09, 0.81) tal events 53 18 eterogeneity: Tau ² = 0.06; Ch ² = 7.70, df = 1 (P = 0.006); l ² = 87% st for overall effect: Z = 2.46 (P = 0.01) 1.6 IL-6 biduljabbar <i>et al.</i> ³⁵ (2018) 30 41 14 44 5.1 0.41 (0.22, 0.61) [Qahtani <i>et al.</i> ³⁴ (2018) 20 40 12 40 4.7 0.20 (-0.01, 0.41) bitotal (95% CI) 81 84 9.8 0.31 (0.10, 0.52) tal events 50 26 eterogeneity: Tau ² = 0.01; Ch ² = 2.16, df = 1 (P = 0.14); l ² = 54% st for overall effect: Z = 2.91 (P = 0.004) 1.7 TNF biduljabbar <i>et al.</i> ³⁵ (2018) 10 41 6 44 5.7 0.11 (-0.06, 0.27) Qahtani <i>et al.</i> ³⁵ (2018) 10 41 6 44 5.7 0.11 (-0.06, 0.27) choral offse CI) 81 84 11.9 0.17 (0.06, 0.29) tal events 20 7 eterogeneity: Tau ² = 0.01; Ch ² = 2.94 (P = 0.029); l ² = 13% st for overall effect: Z = 2.94 (P = 0.000) bital (95% CI) 742 705 100.0 0.16 (0.09, 0.23) tal events 20 7 eterogeneity: Tau ² = 0.00; Ch ² = 1.14, df = 1 (P = 0.29); l ² = 13% st for overall effect: Z = 4.66 (P < 0.00001) bital (95% CI) 742 705 100.0 0.16 (0.09, 0.23) tal events 20 7 eterogeneity: Tau ² = 0.01; Ch ² = 54.99, df = 17 (P < 0.00001); l ² = 69% st for overall effect: Z = 4.66 (P < 0.00001) st for subgroup difference: Ch ² = 8.66, df = 6 (P = 0.19); l ² = 30.7%	Silveira <i>et al</i> . ⁴⁴ (2018)	16	40	10	40	4.9	0.15 (-0.05, 0.35)		
tetrogeniety: Tau ² = 0.00; Chi ² = 0.50, df = 2 ($P = 0.78$); $P = 0\%$ set for overall effect: $Z = 1.98$ ($P = 0.05$) 1.4 karyolysis aderi and Pasha ⁴³ (2017) 4 25 1 25 5.7 0.12 (-0.04, 0.28) liveira <i>et al.</i> ⁴⁴ (2018) 10 40 8 40 5.3 0.05 (-0.13, 0.23) btotal (95% CI) 65 65 11.0 0.09 (-0.03, 0.21) ateria et al. ⁴⁵ (2018) 10 40 8 40 5.8 0.63 (0.46, 0.79) btotal (95% CI) 81 84 10.6 0.45 (0.09, 0.81) btotal (95% CI) 81 84 10.6 0.45 (0.09, 0.81) btotal (95% CI) 81 84 10.6 0.45 (0.09, 0.81) btotal (95% CI) 81 84 9.8 0.31 (0.10, 0.52) tal events 50 26 eterogeneity: Tau ² = 0.06; Chi ² = 7.70, df = 1 ($P = 0.006$); $P = 54\%$ set for overall effect: $Z = 2.91$ ($P = 0.004$) 1.7 TNF bduljabbar <i>et al.</i> ³⁵ (2018) 10 41 6 44 5.7 0.11 (-0.06, 0.27) tal events 50 26 eterogeneity: Tau ² = 0.01; Chi ² = 2.16, df = 1 ($P = 0.29$); $P = 13\%$ set for overall effect: $Z = 2.94$ ($P = 0.003$) 1.7 TNF bduljabbar <i>et al.</i> ³⁵ (2018) 10 41 6 44 5.7 0.11 (-0.06, 0.27) tal events 20 7 tal events 226 104 tal tal t	Subtotal (95% CI)		105		105	15.4	0.11 (0.00, 0.22)		
st for overall effect: $Z = 1.98 (P = 0.05)$ 1.4 karyolysis aderi and Pasha ⁶ (2017) 4 25 1 25 5.7 0.12 (-0.04, 0.28) liveri at <i>d</i> . ⁴⁴ (2018) 10 4 0 8 40 5.3 0.05 (-0.13, 0.23) bitotal (95% CI) 65 65 11.0 0.09 (-0.03, 0.21) stal events 14 9 eterogeneity: Tat ² = 0.00; Chi ² = 0.35, df = 1 (P = 0.55); l ² = 0% st for overall effect: $Z = 1.43 (P = 0.15)$ 1.5 IL-1 biduljabbar et <i>al</i> . ³⁵ (2018) 26 41 16 44 4.8 0.27 (0.07, 0.48) (Qahtani <i>et al</i> . ³⁵ (2018) 26 41 0.2 40 5.8 0.63 (0.46, 0.79) bitotal (95% CI) 81 84 10.6 0.45 (0.09, 0.81) tal events 53 18 eterogeneity: Tat ² = 0.06; Chi ² = 7.70, df = 1 (P = 0.006); l ² = 87% st for overall effect: $Z = 2.46 (P = 0.01)$ 1.6 IL-6 biduljabbar et <i>al</i> . ³⁵ (2018) 30 41 14 44 5.1 0.41 (0.22, 0.61) (Qahtani <i>et al</i> . ⁴⁵ (2018) 20 40 12 40 4.7 0.20 (-0.01, 0.41) bitotal (95% CI) 81 84 9.8 0.31 (0.10, 0.52) tal events 50 26 eterogeneity: Tat ² = 0.01; Chi ² = 2.16, df = 1 (P = 0.14); l ² = 54% st for overall effect: $Z = 2.91 (P = 0.004)$ 1.7 TNF biduljabbar et <i>al</i> . ³⁵ (2018) 10 41 6 44 5.7 0.11 (-0.06, 0.27) (Qahtani <i>et al</i> . ³⁵ (2018) 10 40 1 40 6.2 0.23 (0.08, 0.37) bitotal (95% CI) 81 84 11.9 0.17 (0.06, 0.29) tal events 20 7 tal events 20 7 tal events 226 104 eterogeneity: Tat ² = 0.00; Chi ² = 1.14, df = 1 (P = 0.09); l ² = 13% est for overall effect: $Z = 2.94 (P = 0.003)$ 1.5 1.6 1.6 (P = 0.000) 1.6 1.9 5.5 9 0.6 1.7 (P < 0.000001); l ² = 69% est for overall effect: $Z = 2.94 (P = 0.0003)$ 1.7 0.5 0 0.5 Non-smokers waterpipe	Fotal events		a (*						
1.4 karyolysis aderi and Pasha ⁶ (2017) 4 25 1 25 5.7 0.12 (-0.04, 0.28) lveira <i>et al.</i> ⁴⁴ (2018) 10 40 8 40 5.3 0.05 (-0.13, 0.23) bitotal (95% CI) 65 65 11.0 0.09 (-0.03, 0.21) stal events 14 9 eterogeneity: Tau ² = 0.00; Chi ² = 0.35, df = 1 ($P = 0.55$); $I^2 = 0$ % set for overall effect: $Z = 1.43$ ($P = 0.15$) 1.5 IL-1 bitotal (95% CI) 81 84 10.6 0.45 (0.09, 0.81) stal events 53 18 eterogeneity: Tau ² = 0.06; Chi ² = 7.70, df = 1 ($P = 0.006$); $I^2 = 87$ % set for overall effect: $Z = 2.46$ ($P = 0.01$) 1.6 IL-6 bitotal (95% CI) 81 84 10.6 0.45 (0.09, 0.81) stal events 53 26 eterogeneity: Tau ² = 0.06; Chi ² = 7.70, df = 1 ($P = 0.006$); $I^2 = 87$ % set for overall effect: $Z = 2.46$ ($P = 0.01$) 1.6 IL-6 bitotal (95% CI) 81 84 98 0.31 (0.10, 0.52) stal events 50 26 eterogeneity: Tau ² = 0.00; Chi ² = 2.16, df = 1 ($P = 0.14$); $I^2 = 54\%$ set for overall effect: $Z = 2.91$ ($P = 0.004$) 1.7 TNF bitotal (95% CI) 20 77 72 tetrogeneity: Tau ² = 0.00; Chi ² = 1.14, df = 1 ($P = 0.29$); $I^2 = 13\%$ set for overall effect: $Z = 2.94$ ($P = 0.003$) tal events 226 104 eterogeneity: Tau ² = 0.00; Chi ² = 1.17, Qf = 1.17 ($P = 0.29$); $I^2 = 13\%$ set for overall effect: $Z = 2.94$ ($P = 0.003$) tal events 226 104 eterogeneity: Tau ² = 0.00; Chi ² = 54.99, df = 17 ($P = 0.200$); $I^2 = 69\%$ set for overall effect: $Z = 4.66$ ($P = 0.0001$); $I^2 = 69\%$ set for overall effect: $Z = 4.66$ ($P = 0.0001$); $I^2 = 69\%$ set for overall effect: $Z = 4.66$ ($P = 0.0001$); $I^2 = 69\%$ set for overall effect: $Z = 4.66$ ($P = 0.0001$); $I^2 = 69\%$ set for overall effect: $Z = 4.66$ ($P = 0.0001$); $I^2 = 69\%$ set for subgroup difference: Chi ² = 8.66, df = 6 ($P = 0.19$); $I^2 = 30.7\%$			= 2 (<i>P</i> =	0.78); I ² =	0%				
aderi and Pasha ⁴⁸ (2017) 4 25 1 25 5.7 0.12 ($.0.04, 0.28$) lveira <i>et al.</i> ⁴⁴ (2018) 10 40 8 40 5.3 0.05 ($.0.13, 0.23$) bitotal (95% CI) 65 65 11.0 0.09 ($-0.03, 0.21$) at al events 14 9 eterogeneity: Tau ² = 0.00; Cht ² = 0.35, df = 1 ($P = 0.55$); $I^2 = 0\%$ set for overall effect: $Z = 1.43$ ($P = 0.15$) 1.51L-1 bitotal (95% CI) 84 41 16 44 4.8 0.27 ($0.07, 0.48$) lQahtari <i>et al.</i> ³⁴ (2018) 26 41 16 44 4.8 0.27 ($0.07, 0.48$) lQahtari <i>et al.</i> ³⁴ (2018) 27 40 2 40 5.8 0.63 ($0.46, 0.79$) bitotal (95% CI) 81 84 10.6 0.45 ($0.09, 0.81$) tal events 53 18 eterogeneity: Tau ² = 0.06; Cht ² = 7.70, df = 1 ($P = 0.006$); $I^2 = 87\%$ est for overall effect: $Z = 2.46$ ($P = 0.01$) 1.61L-6 bidulalbar <i>et al.</i> ³⁵ (2018) 30 41 14 44 5.1 0.41 ($0.22, 0.61$) lQahtari <i>et al.</i> ³⁵ (2018) 30 41 14 44 5.1 0.41 ($0.22, 0.61$) lQahtari <i>et al.</i> ³⁵ (2018) 20 40 12 40 4.7 0.20 ($-0.01, 0.41$)) bitotal (95% CI) 81 84 9.8 0.31 ($0.10, 0.52$) eterogeneity: Tau ² = 0.01; Cht ² = 2.16, df = 1 ($P = 0.14$); $I^2 = 54\%$ est for overall effect: $Z = 2.91$ ($P = 0.004$) 1.7 TNF bidulalbar <i>et al.</i> ³⁵ (2018) 10 41 6 44 5.7 0.11 ($-0.06, 0.27$) (bitotal (95% CI) 81 84 119 0.17 ($0.06, 0.29$)) tal events 20 7 eterogeneity: Tau ² = 0.00; Cht ² = 1.14, df = 1 ($P = 0.29$); $I^2 = 13\%$ est for overall effect: $Z = 2.94$ ($P = 0.003$) bitotal (95% CI) 742 705 100.0 0.16 ($0.09, 0.23$) tal events 226 104 eterogeneity: Tau ² = 0.01; Cht ² = 54.99, df = 17 ($P = 0.0001$); $I^2 = 69\%$ est for overall effect: $Z = 4.66$ ($P = 0.0001$) tal events 226 104 eterogeneity: Tau ² = 0.01; Cht ² = 54.99, df = 17 ($P = 0.0001$); $I^2 = 69\%$ est for overall effect: $Z = 4.66$ ($P = 0.0001$) tal events 226 104 eterogeneity: Tau ² = 0.01; Cht ² = 54.99, df = 17 ($P = 0.00001$); $I^2 = 69\%$ est for overall effect: $Z = 4.66$ ($P = 0.00001$) eterogeneity: Tau ² = 0.01; Cht ² = 54.99, df = 17 ($P = 0.00001$); $I^2 = 69\%$ est for overall effect: $Z = 4.66$ ($P = 0.00001$) eterogeneity: Tau ² = 0.01		(1 = 0.05)							
like at al^{44} (2018) 10 40 8 40 5.3 0.05 (-0.13, 0.23) bit otal (95% CI) 65 65 11.0 0.09 (-0.03, 0.21) bit otal events 14 9 eterogeneity: Tau ² = 0.00; Ch ² = 0.35, df = 1 ($P = 0.55$); l ² = 0% isst for overall effect: $Z = 1.43$ ($P = 0.15$) 1.51L-1 bit otal events 2 40 5.8 0.63 (0.46, 0.79) bit otal (95% CI) 81 84 10.6 0.45 (0.09, 0.81) tal events 53 18 eterogeneity: Tau ² = 0.06; Ch ² = 7.70, df = 1 ($P = 0.006$); l ² = 87% ist for overall effect: $Z = 2.46$ ($P = 0.01$) 1.6 L-6 bid uljabbar et $al^{.34}$ (2018) 20 40 12 40 4.7 0.20 (-0.01, 0.41) bit otal (95% CI) 81 84 9.8 0.31 (0.10, 0.52) tal events 50 26 eterogeneity: Tau ² = 0.01; Ch ² = 2.16, df = 1 ($P = 0.14$); l ² = 54% ist for overall effect: $Z = 2.91$ ($P = 0.004$) 1.7 TNF bid uljabbar et $al^{.35}$ (2018) 10 41 6 44 5.7 0.11 (-0.06, 0.27) (Qahtan i et $al^{.34}$ (2018) 10 40 1 40 6.2 0.23 (0.08, 0.37) bit otal events 20 7 eterogeneity: Tau ² = 0.00; Ch ² = 1.14, df = 1 ($P = 0.29$); l ² = 13% ist for overall effect: $Z = 2.94$ ($P = 0.003$) bit al events 20 7 eterogeneity: Tau ² = 0.01; Ch ² = 54.99, df = 17 ($P = 0.00001$); l ² = 69% ist for overall effect: $Z = 4.66$ ($P < 0.0001$) bit al events 226 104 eterogeneity: Tau ² = 0.01; Ch ² = 54.99, df = 17 ($P = 0.00001$); l ² = 69% ist for overall effect: $Z = 4.66$ ($P < 0.0001$) ist for subgroup difference: Ch ² = 8.66, df = 6 ($P = 0.19$); l ² = 30.7%	1.1.4 karyolysis	4	05	1	05		0.10 (0.04 0.20)		
bitotal (95% CI) 65 65 11.0 $0.09 (-0.03, 0.21)$ tal events 14 9 eterogeneity: Tau ² = 0.00; Chi ² = 0.35, df = 1 (P = 0.55); l ² = 0% est for overall effect: Z = 1.43 (P = 0.15) L5 IL-1 bitotal (95% CI) 81 84 10.6 0.45 (0.09, 0.81) tal events 53 18 eterogeneity: Tau ² = 0.06; Chi ² = 7.70, df = 1 (P = 0.006); l ² = 87% set for overall effect: Z = 2.46 (P = 0.01) L6 IL-6 bitotal (95% CI) 81 84 9.8 0.31 (0.10, 0.52) tal events 50 26 eterogeneity: Tau ² = 0.01; Chi ² = 2.16, df = 1 (P = 0.14); l ² = 54% set for overall effect: Z = 2.91 (P = 0.004) L7 TNF bitotal (95% CI) 742 705 100.0 0.16 (0.09, 0.23) tal events 20 7 eterogeneity: Tau ² = 0.00; Chi ² = 1.14, df = 1 (P = 0.29); l ² = 13% set for overall effect: Z = 2.94 (P = 0.003) tal events 20 7 eterogeneity: Tau ² = 0.01; Chi ² = 54.90, df = 17 (P = 0.0001); l ² = 69% set for overall effect: Z = 4.66 (P < 0.00001) set for overall effect: Z = 4.66 (P < 0.00001) set for overall effect: Z = 4.66 (P < 0.00001) set for overall effect: Z = 4.66 (P < 0.00001) set for overall effect: Z = 4.66 (P < 0.00001) set for overall effect: Z = 4.66 (P < 0.00001) set for overall effect: Z = 4.66 (P < 0.00001) set for overall effect: Z = 4.66 (P < 0.00001) set for overall effect: Z = 4.66 (P < 0.00001) set for subgroup difference: Chi ² = 8.66, df = 6 (P = 0.19); l ² = 30.7%								_ _	
tal events 14 9 teterogeneity: Tau ² = 0.00; Chi ² = 0.35, df = 1 ($P = 0.55$); l ² = 0% set for overall effect: Z = 1.43 ($P = 0.15$) 1.5 IL-1 bduljabbar <i>et al.</i> ³⁵ (2018) 26 41 16 44 4.8 0.27 (0.07, 0.48) (Qahtani <i>et al.</i> ³⁶ (2018) 27 40 2 40 5.8 0.63 (0.46, 0.79) btotal (95% CI) 81 84 10.6 0.45 (0.09, 0.81) tal events 53 18 teterogeneity: Tau ² = 0.06; Chi ² = 7.70, df = 1 ($P = 0.006$); l ² = 87% set for overall effect: Z = 2.46 ($P = 0.01$) 1.6 IL-6 bduljabbar <i>et al.</i> ³⁶ (2018) 30 41 14 44 5.1 0.41 (0.22, 0.61) (Qahtani <i>et al.</i> ³⁶ (2018) 20 40 12 40 4.7 0.20 (-0.01, 0.41) bdula (95% CI) 81 84 9.8 0.31 (0.10, 0.52) teterogeneity: Tau ² = 0.01; Chi ² = 2.16, df = 1 ($P = 0.14$); l ² = 54% set for overall effect: Z = 2.91 ($P = 0.004$) 1.7 TNF bduljabbar <i>et al.</i> ³⁵ (2018) 10 41 6 44 5.7 0.11 (-0.06, 0.27) (Qahtani <i>et al.</i> ³⁴ (2018) 10 40 1 40 6.2 0.23 (0.08, 0.37) bdotal (95% CI) 81 84 11.9 0.17 (0.06, 0.29) reterogeneity: Tau ² = 0.00; Chi ² = 1.14, df = 1 ($P = 0.29$); l ² = 13% set for overall effect: Z = 2.94 ($P = 0.003$) btotal events 20 7 eterogeneity: Tau ² = 0.01; Chi ² = 54.99, df = 17 ($P < 0.00001$); l ² = 69% set for overall effect: Z = 4.66 ($P < 0.00001$) btotal events 216 104 ctrospeneity: Tau ² = 0.01; Chi ² = 54.99, df = 17 ($P < 0.00001$); l ² = 69% set for overall effect: Z = 4.66 ($P < 0.00001$) btotal events 216 104 ctrospeneity: Tau ² = 0.01; Chi ² = 54.99, df = 17 ($P < 0.00001$); l ² = 69% set for overall effect: Z = 4.66 ($P < 0.00001$) btotal events 216 104 ctrospeneity: Tau ² = 0.01; Chi ² = 54.60, df = 6 ($P = 0.19$); l ² = 30.7%		10		0				•	
eterogeneity: Tau ² = 0.00; Chi ² = 0.35, df = 1 ($P = 0.55$); $I^{2} = 0\%$ st for overall effect: $Z = 1.43$ ($P = 0.15$) 1.5 IL-1 bduljabbar <i>et al.</i> ³⁵ (2018) 26 41 16 44 4.8 0.27 (0.07, 0.48) [Qaltani <i>et al.</i> ³⁴ (2018) 27 40 2 40 5.8 0.63 (0.46, 0.79) 1.btotal (95% CI) 81 84 10.6 0.45 (0.09, 0.81) tal events 53 18 eterogeneity: Tau ² = 0.06; Chi ² = 7.70, df = 1 ($P = 0.006$); $I^{2} = 87\%$ est for overall effect: $Z = 2.46$ ($P = 0.01$) 1.6 IL-6 bduljabbar <i>et al.</i> ³⁵ (2018) 30 41 14 44 5.1 0.41 (0.22, 0.61) [Qaltani <i>et al.</i> ³⁴ (2018) 20 40 12 40 4.7 0.20 (-0.01, 0.41) 1.btotal (95% CI) 81 84 9.8 0.31 (0.10, 0.52) tal events 50 26 eterogeneity: Tau ² = 0.01; Chi ² = 2.16, df = 1 ($P = 0.14$); $I^{2} = 54\%$ st for overall effect: $Z = 2.91$ ($P = 0.004$) 1.7 TNF bduljabbar <i>et al.</i> ³⁵ (2018) 10 41 6 44 5.7 0.11 (-0.06, 0.27) [Qaltani <i>et al.</i> ³⁴ (2018) 10 40 1 40 6.2 0.23 (0.08, 0.37) btotal (95% CI) 81 84 11.9 0.17 (0.06, 0.29) tal events 20 7 eterogeneity: Tau ² = 0.00; Chi ² = 1.14, df = 1 ($P = 0.29$); $I^{2} = 13\%$ est for overall effect: $Z = 2.94$ ($P = 0.003$) btal events 20 7 eterogeneity: Tau ² = 0.01; Chi ² = 54.99, df = 17 ($P < 0.00001$); $I^{2} = 69\%$ est for overall effect: $Z = 2.94$ ($P = 0.003$) btal events 226 104 eterogeneity: Tau ² = 0.01; Chi ² = 54.99, df = 17 ($P < 0.00001$); $I^{2} = 69\%$ est for overall effect: $Z = 2.94$ ($P = 0.003$) btal events 226 104 eterogeneity: Tau ² = 0.01; Chi ² = 54.99, df = 17 ($P < 0.00001$); $I^{2} = 69\%$ est for overall effect: $Z = 4.66$ ($P < 0.00001$) est for subgroup difference: Chi ² = 8.66, df = 6 ($P = 0.19$); $I^{2} = 30.7\%$		14	05	9	05	11.0	0.09 (-0.05, 0.21)		
est for overall effect: $Z = 1.43 (P = 0.15)$ 1.5 IL-1 bduljabbar et $al.^{35} (2018)$ 26 41 16 44 4.8 0.27 (0.07, 0.48) (Qaltani et $al.^{34} (2018)$ 27 40 2 40 5.8 0.63 (0.46, 0.79) blototal (95% CI) 81 84 10.6 0.45 (0.09, 0.81) at events 53 18 eterogeneity: Tau ² = 0.06; Chi ² = 7.70, df = 1 (P = 0.006); I ² = 87% est for overall effect: $Z = 2.46 (P = 0.01)$ 1.6 IL-6 bduljabbar et $al.^{34} (2018)$ 20 40 12 40 4.7 0.20 (-0.01, 0.41) blotal (95% CI) 81 84 9.8 0.31 (0.10, 0.52) btal events 50 26 eterogeneity: Tau ² = 0.01; Chi ² = 2.16, df = 1 (P = 0.14); I ² = 54% est for overall effect: $Z = 2.91 (P = 0.004)$ 1.7 TNF bduljabbar et $al.^{35} (2018)$ 10 41 6 44 5.7 0.11 (-0.06, 0.27) (Qaltani et $al.^{34} (2018)$ 10 40 1 400 6.2 0.23 (0.08, 0.37) blototal (95% CI) 81 84 11.9 0.17 (0.06, 0.29) ptal events 20 7 eterogeneity: Tau ² = 0.00; Chi ² = 1.14, df = 1 (P = 0.29); I ² = 13% est for overall effect: $Z = 2.94 (P = 0.003)$ btal events 226 104 eterogeneity: Tau ² = 0.01; Chi ² = 54.99, df = 17 (P < 0.00001); I ² = 69% est for overall effect: $Z = 4.66 (P < 0.00001)$ est for overall effect: $Z = 4.66 (P < 0.00001)$ est for subgroup difference: Chi ² = 8.66, df = 6 (P = 0.19); I ² = 30.7%			= 1 (<i>P</i> =		0%				
bduljabbar et al^{35} (2018) 26 41 16 44 4.8 0.27 (0.07, 0.48) [Qaltani et al^{34} (2018) 27 40 2 40 5.8 0.63 (0.46, 0.79) btotal (95% CI) 81 84 10.6 0.45 (0.09, 0.81) tal events 53 18 eterogeneity: Tau ² = 0.06; Ch ² = 7.70, df = 1 ($P = 0.006$); I ² = 87% set for overall effect: Z = 2.46 ($P = 0.01$) 1.6 IL-6 bduljabbar et al^{34} (2018) 30 41 14 44 5.1 0.41 (0.22, 0.61) [Qaltani et al^{34} (2018) 20 40 12 40 4.7 0.20 (-0.01, 0.41) btotal (95% CI) 81 84 9.8 0.31 (0.10, 0.52) tal events 50 26 eterogeneity: Tau ² = 0.01; Chi ² = 2.16, df = 1 ($P = 0.14$); I ² = 54% set for overall effect: Z = 2.91 ($P = 0.004$) 1.7 TNF bduljabbar et al^{35} (2018) 10 41 6 44 5.7 0.11 (-0.06, 0.27) [Qaltani et al^{34} (2018) 10 40 1 40 6.2 0.23 (0.08, 0.37) btotal (95% CI) 81 84 11.9 0.17 (0.06, 0.29) tal events 20 7 eterogeneity: Tau ² = 0.00; Chi ² = 1.14, df = 1 ($P = 0.29$); I ² = 13% set for overall effect: Z = 2.94 ($P = 0.003$) btal events 226 104 eterogeneity: Tau ² = 0.01; Chi ² = 54.99, df = 17 ($P < 0.00001$); I ² = 69% set for overall effect: Z = 4.66 ($P < 0.00001$) eterogeneity: Tau ² = 0.01; Chi ² = 54.99, df = 17 ($P < 0.00001$); I ² = 69% set for overall effect: Z = 4.66 ($P < 0.00001$) eterogeneity: Tau ² = 0.01; Chi ² = 54.99, df = 17 ($P < 0.00001$); I ² = 69% set for overall effect: Z = 4.66 ($P < 0.00001$) eterogeneity: Tau ² = 0.01; Chi ² = 8.66, df = 6 ($P = 0.19$); I ² = 30.7%									
IQahtani <i>et al.</i> ³⁴ (2018) 27 40 2 40 5.8 0.63 (0.46, 0.79) bitotal (95% CI) 81 84 10.6 0.45 (0.09, 0.81) tal events 53 18 eterogeneity: Tau ² = 0.06; Chi ² = 7.70, df = 1 ($P = 0.006$); l ² = 87% est for overall effect: $Z = 2.46$ ($P = 0.01$) 1.6 IL-6 bduljabbar <i>et al.</i> ³⁵ (2018) 30 41 14 44 5.1 0.41 (0.22, 0.61) Qahtani <i>et al.</i> ³⁴ (2018) 20 40 12 40 4.7 0.20 (-0.01, 0.41) bitotal (95% CI) 81 84 9.8 0.31 (0.10, 0.52) otal events 50 26 eterogeneity: Tau ² = 0.01; Chi ² = 2.16, df = 1 ($P = 0.14$); l ² = 54% est for overall effect: $Z = 2.91$ ($P = 0.004$) 1.7 TNF bduljabbar <i>et al.</i> ³⁵ (2018) 10 41 6 44 5.7 0.11 (-0.06, 0.27) Qahtani <i>et al.</i> ³⁴ (2018) 10 40 1 40 6.2 0.23 (0.08, 0.37) bitotal (95% CI) 81 84 11.9 0.17 (0.06, 0.29) otal events 20 7 eterogeneity: Tau ² = 0.00; Chi ² = 1.14, df = 1 ($P = 0.29$); l ² = 13% est for overall effect: $Z = 2.94$ ($P = 0.003$) bal (95% CI) 742 705 100.0 0.16 (0.09, 0.23) otal events 226 104 eterogeneity: Tau ² = 0.01; Chi ² = 54.99, df = 17 ($P < 0.00001$); l ² = 69% est for overall effect: $Z = 4.66$ ($P < 0.00001$) est for subgroup difference: Chi ² = 8.66, df = 6 ($P = 0.19$); l ² = 30.7%	1.1.5 IL-1								
bitotal (95% CI) 81 84 10.6 0.45 (0.09, 0.81) tal events 53 18 eterogeneity: Tau ² = 0.06; Ch ² = 7.70, df = 1 ($P = 0.006$); l ² = 87% set for overall effect: $Z = 2.46$ ($P = 0.01$) 1.6 IL-6 bituljabbar <i>et al.</i> ³⁵ (2018) 30 41 14 44 5.1 0.41 (0.22, 0.61) IQahtani <i>et al.</i> ³⁴ (2018) 20 40 12 40 4.7 0.20 (-0.01, 0.41) bitotal (95% CI) 81 84 9.8 0.31 (0.10, 0.52) tal events 50 26 eterogeneity: Tau ² = 0.01; Ch ² = 2.16, df = 1 ($P = 0.14$); l ² = 54% set for overall effect: $Z = 2.91$ ($P = 0.004$) 1.7 TNF bitul (95% CI) 81 84 11.9 0.17 (0.06, 0.27) IQahtani <i>et al.</i> ³⁴ (2018) 10 40 1 40 6.2 0.23 (0.08, 0.37) bitul (95% CI) 742 705 100.0 0.16 (0.09, 0.23) tal events 20 7 eterogeneity: Tau ² = 0.00; Ch ² = 1.14, df = 1 ($P = 0.29$); l ² = 13% set for overall effect: $Z = 2.94$ ($P = 0.003$) bitul (95% CI) 742 705 100.0 0.16 (0.09, 0.23) tal events 226 104 eterogeneity: Tau ² = 0.01; Ch ² = 54.99, df = 17 ($P = 0.00001$); l ² = 69% set for overall effect: $Z = 4.66$ ($P < 0.00001$) eterogeneity: Tau ² = 0.01; Ch ² = 54.99, df = 17 ($P = 0.00001$); l ² = 30.7%	Abduljabbar <i>et al.</i> ³⁵ (2018)	26	41		44	4.8	0.27 (0.07, 0.48)		
bale verits 53 18 tetrogeneity: Tau ² = 0.06; Chi ² = 7.70, df = 1 ($P = 0.006$); I ² = 87% est for overall effect: $Z = 2.46$ ($P = 0.01$) 1.6 IL-6 bduljabbar <i>et al.</i> ³⁵ (2018) 30 41 14 44 5.1 0.41 (0.22, 0.61) IQahtani <i>et al.</i> ³⁴ (2018) 20 40 12 40 4.7 0.20 (-0.01, 0.41) bibotal (95% CI) 81 84 9.8 0.31 (0.10, 0.52) stal events 50 26 tetrogeneity: Tau ² = 0.01; Chi ² = 2.16, df = 1 ($P = 0.14$); I ² = 54% est for overall effect: $Z = 2.91$ ($P = 0.004$) 1.7 TNF bduljabbar <i>et al.</i> ³⁵ (2018) 10 41 6 44 5.7 0.11 (-0.06, 0.27) IQahtani <i>et al.</i> ³⁴ (2018) 10 40 1 40 6.2 0.23 (0.08, 0.37) ubtotal (95% CI) 81 84 11.9 0.17 (0.06, 0.29) stal events 20 7 eterogeneity: Tau ² = 0.00; Chi ² = 1.14, df = 1 ($P = 0.29$); I ² = 13% est for overall effect: $Z = 2.94$ ($P = 0.003$) btal events 226 104 eterogeneity: Tau ² = 0.01; Chi ² = 54.99, df = 17 ($P < 0.00001$); I ² = 69% est for overall effect: $Z = 4.66$ ($P < 0.00001$) est for subgroup difference: Chi ² = 8.66, df = 6 ($P = 0.19$); I ² = 30.7%	AlQahtani <i>et al.</i> ³⁴ (2018)	27		2	40		(, , ,		
eterogeneity: Tau ² = 0.06; Chi ² = 7.70, df = 1 ($P = 0.006$); I ² = 87% est for overall effect: Z = 2.46 ($P = 0.01$) 1.6 IL-6 bduljabbar <i>et al.</i> ³⁵ (2018) 30 41 14 44 5.1 0.41 (0.22, 0.61) Qahtani <i>et al.</i> ³⁴ (2018) 20 40 12 40 4.7 0.20 (-0.01, 0.41) btotal (95% CI) 81 84 9.8 0.31 (0.10, 0.52) tal events 50 26 eterogeneity: Tau ² = 0.01; Chi ² = 2.16, df = 1 ($P = 0.14$); I ² = 54% est for overall effect: Z = 2.91 ($P = 0.004$) 1.7 TNF bduljabbar <i>et al.</i> ³⁵ (2018) 10 41 6 44 5.7 0.11 (-0.06, 0.27) Qahtani <i>et al.</i> ³⁵ (2018) 10 40 1 40 6.2 0.23 (0.08, 0.37) btotal (95% CI) 81 84 11.9 0.17 (0.06, 0.29) tal events 20 7 eterogeneity: Tau ² = 0.00; Chi ² = 1.14, df = 1 ($P = 0.29$); I ² = 13% est for overall effect: Z = 2.94 ($P = 0.003$) btal events 226 104 eterogeneity: Tau ² = 0.01; Chi ² = 54.99, df = 17 ($P < 0.00001$); I ² = 69% est for overall effect: Z = 4.66 ($P < 0.00001$) est for subgroup difference: Chi ² = 8.66, df = 6 ($P = 0.19$); I ² = 30.7%	Subtotal (95% CI)		81		84	10.6	0.45 (0.09, 0.81)		
est for overall effect: $Z = 2.46 (P = 0.01)$ 1.6 IL-6 bdu]jabbar et al. ³⁵ (2018) 30 41 14 44 5.1 0.41 (0.22, 0.61) IQahtani et al. ³⁴ (2018) 20 40 12 40 4.7 0.20 (-0.01, 0.41) ubtotal (95% CI) 81 84 9.8 0.31 (0.10, 0.52) tal events 50 26 eterogeneity: Tau ² = 0.01; Chi ² = 2.16, df = 1 (P = 0.14); I ² = 54% est for overall effect: $Z = 2.91 (P = 0.004)$ 1.7 TNF bdu]jabbar et al. ³⁴ (2018) 10 41 6 44 5.7 0.11 (-0.06, 0.27) IQahtani et al. ³⁴ (2018) 10 40 1 40 6.2 0.23 (0.08, 0.37) ubtotal (95% CI) 81 84 11.9 0.17 (0.06, 0.29) otal events 20 7 eterogeneity: Tau ² = 0.00; Chi ² = 1.14, df = 1 (P = 0.29); I ² = 13% est for overall effect: $Z = 2.94 (P = 0.003)$ bal (95% CI) 742 705 100.0 0.16 (0.09, 0.23) otal events 226 104 eterogeneity: Tau ² = 0.01; Chi ² = 54.99, df = 17 (P < 0.00001); I ² = 69% est for overall effect: $Z = 4.66 (P < 0.00001)$ est for subgroup difference: Chi ² = 8.66, df = 6 (P = 0.19); I ² = 30.7%	Total events		1 / 17		070/				
1.6 IL-6 bduljabbar <i>et al.</i> ³⁵ (2018) 30 41 14 44 5.1 0.41 (0.22, 0.61) IQahtani <i>et al.</i> ³⁴ (2018) 20 40 12 40 4.7 0.20 (-0.01, 0.41) bitotal (95% CI) 81 84 9.8 0.31 (0.10, 0.52) btal events 50 26 eterogeneity: Tau ² = 0.01; Chi ² = 2.16, df = 1 ($P = 0.14$); I ² = 54% est for overall effect: $Z = 2.91$ ($P = 0.004$) 1.7 TNF bduljabbar <i>et al.</i> ³⁵ (2018) 10 41 6 44 5.7 0.11 (-0.06, 0.27) IQahtani <i>et al.</i> ³⁴ (2018) 10 40 1 40 6.2 0.23 (0.08, 0.37) bitotal (95% CI) 81 84 11.9 0.17 (0.06, 0.29) btal events 20 7 eterogeneity: Tau ² = 0.00; Chi ² = 1.14, df = 1 ($P = 0.29$); I ² = 13% est for overall effect: $Z = 2.94$ ($P = 0.003$) btal (95% CI) 742 705 100.0 0.16 (0.09, 0.23) btal (95% CI) 742 705 100.0 0.16 (0.09, 0.23) btal (95% CI) 742 705 100.0 0.16 (0.09, 0.23) btal events 226 104 eterogeneity: Tau ² = 0.01; Chi ² = 54.99, df = 17 ($P < 0.00001$); I ² = 69% est for overall effect: $Z = 4.66$ ($P < 0.00001$) est for subgroup difference: Chi ² = 8.66, df = 6 ($P = 0.19$); I ² = 30.7%			= 1 (<i>P</i> =	0.006); 1 ² =	= 87%				
bduljabbar <i>et al.</i> ³⁵ (2018) 30 41 14 44 5.1 0.41 (0.22, 0.61) IQahtani <i>et al.</i> ³⁴ (2018) 20 40 12 40 4.7 0.20 (-0.01, 0.41) btotal (95% CI) 81 84 9.8 0.31 (0.10, 0.52) otal events 50 26 eterogeneity: Tau ² = 0.01; Chi ² = 2.16, df = 1 ($P = 0.14$); I ² = 54% est for overall effect: $Z = 2.91$ ($P = 0.004$) 1.7 TNF bduljabbar <i>et al.</i> ³⁵ (2018) 10 41 6 444 5.7 0.11 (-0.06, 0.27) IQahtani <i>et al.</i> ³⁴ (2018) 10 40 1 40 6.2 0.23 (0.08, 0.37) btotal (95% CI) 81 84 11.9 0.17 (0.06, 0.29) otal events 20 7 eterogeneity: Tau ² = 0.00; Chi ² = 1.14, df = 1 ($P = 0.29$); I ² = 13% est for overall effect: $Z = 2.94$ ($P = 0.003$) btal (95% CI) 742 705 100.0 0.16 (0.09, 0.23) otal (95% CI) 742 705 100.0 0.16 (0.09, 0.23) eterogeneity: Tau ² = 0.01; Chi ² = 54.99, df = 17 ($P < 0.00001$); I ² = 69% est for overall effect: $Z = 4.66$ ($P < 0.00001$) est for subgroup difference: Chi ² = 8.66, df = 6 ($P = 0.19$); I ² = 30.7%	L = 2.46	(<i>r</i> [*] = 0.01)							
IQahtani <i>et al.</i> ³⁴ (2018) 20 40 12 40 4.7 0.20 (-0.01, 0.41) abtotal (95% CI) 81 84 9.8 0.31 (0.10, 0.52) tal events 50 26 eterogeneity: Tau ² = 0.01; Chi ² = 2.16, df = 1 ($P = 0.14$); I ² = 54% est for overall effect: Z = 2.91 ($P = 0.004$) 1.7 TNF bduljabbar <i>et al.</i> ³⁵ (2018) 10 41 6 44 5.7 0.11 (-0.06, 0.27) IQahtani <i>et al.</i> ³⁴ (2018) 10 40 1 40 6.2 0.23 (0.08, 0.37) bdtal (95% CI) 81 84 11.9 0.17 (0.06, 0.29) otal events 20 7 eterogeneity: Tau ² = 0.00; Chi ² = 1.14, df = 1 ($P = 0.29$); I ² = 13% est for overall effect: Z = 2.94 ($P = 0.003$) btal (95% CI) 742 705 100.0 0.16 (0.09, 0.23) tal events 226 104 eterogeneity: Tau ² = 0.01; Chi ² = 54.99, df = 17 ($P < 0.0001$); I ² = 69% est for overall effect: Z = 4.66 ($P < 0.00001$) est for subgroup difference: Chi ² = 8.66, df = 6 ($P = 0.19$); I ² = 30.7%	1.1.6 IL-6 Abduliabbar <i>et al</i> ³⁵ (2018)	30	41	14	4.4	5.1	0.41 (0.22, 0.61)		
abiotal (95% CI) bial events bial events bial events constrained for events con								<u> </u>	
ball events 50 26 eterogeneity: Tau ² = 0.01; Chi ² = 2.16, df = 1 (<i>P</i> = 0.14); I ² = 54% est for overall effect: <i>Z</i> = 2.91 (<i>P</i> = 0.004) 1.7 TNF bduljabbar <i>et al.</i> ³⁵ (2018) 10 41 6 44 5.7 0.11 (-0.06, 0.27) lgahtani <i>et al.</i> ³⁴ (2018) 10 40 1 40 6.2 0.23 (0.08, 0.37) lbtotal (95% CI) 81 84 11.9 0.17 (0.06, 0.29) btal events 20 7 eterogeneity: Tau ² = 0.00; Chi ² = 1.14, df = 1 (<i>P</i> = 0.29); I ² = 13% est for overall effect: <i>Z</i> = 2.94 (<i>P</i> = 0.003) btal events 226 104 eterogeneity: Tau ² = 0.01; Chi ² = 54.99, df = 17 (<i>P</i> < 0.00001); I ² = 69% est for overall effect: <i>Z</i> = 4.66 (<i>P</i> < 0.00001) est for subgroup difference: Chi ² = 8.66, df = 6 (<i>P</i> = 0.19); I ² = 30.7%	Subtotal (95% CI)	20		14				-	
eterogeneity: Tau ² = 0.01; Chi ² = 2.16, df = 1 ($P = 0.14$); I ² = 54% est for overall effect: Z = 2.91 ($P = 0.004$) 1.7 TNF bduljabbar <i>et al.</i> ³⁵ (2018) 10 41 6 44 5.7 0.11 (-0.06, 0.27) lQahtani <i>et al.</i> ³⁴ (2018) 10 40 1 40 6.2 0.23 (0.08, 0.37) bbotal (95% CI) 81 84 11.9 0.17 (0.06, 0.29) tal events 20 7 eterogeneity: Tau ² = 0.00; Chi ² = 1.14, df = 1 ($P = 0.29$); I ² = 13% est for overall effect: Z = 2.94 ($P = 0.003$) btal (95% CI) 742 705 100.0 0.16 (0.09, 0.23) eterogeneity: Tau ² = 0.01; Chi ² = 54.99, df = 17 ($P < 0.00001$); I ² = 69% est for overall effect: Z = 4.66 ($P < 0.00001$) est for subgroup difference: Chi ² = 8.66, df = 6 ($P = 0.19$); I ² = 30.7%	Fotal events	50				210			
est for overall effect: $Z = 2.91$ ($P = 0.004$) 1.7 TNF bduljabbar <i>et al.</i> ³⁵ (2018) 10 41 6 44 5.7 0.11 (-0.06, 0.27) IQahtani <i>et al.</i> ³⁴ (2018) 10 40 1 40 6.2 0.23 (0.08, 0.37) 1btotal (95% CI) 81 84 11.9 0.17 (0.06, 0.29) tal events 20 7 eterogeneity: Tau ² = 0.00; Chi ² = 1.14, df = 1 ($P = 0.29$); $I2 = 13\%$ est for overall effect: $Z = 2.94$ ($P = 0.003$) btal (95% CI) 742 705 100.0 0.16 (0.09, 0.23) btal (95% CI) 742 705 100.0 0.16 (0.09, 0.23) btal events 226 104 eterogeneity: Tau ² = 0.01; Chi ² = 54.99, df = 17 ($P < 0.00001$); $I2 = 69\%$ est for overall effect: $Z = 4.66$ ($P < 0.00001$) est for subgroup difference: Chi ² = 8.66, df = 6 ($P = 0.19$); $I2 = 30.7\%$	Heterogeneity: Tau ² = 0.01; Ch	i ² = 2.16, df	= 1 (<i>P</i> =		54%				
bduljabbar <i>et al.</i> ³⁵ (2018) 10 41 6 44 5.7 0.11 (-0.06, 0.27) IQahtani <i>et al.</i> ³⁴ (2018) 10 40 1 40 6.2 0.23 (0.08, 0.37) btotal (95% CI) 81 84 11.9 0.17 (0.06, 0.29) otal events 20 7 eterogeneity: Tau ² = 0.00; Chi ² = 1.14, df = 1 ($P = 0.29$); I ² = 13% est for overall effect: $Z = 2.94$ ($P = 0.003$) otal (95% CI) 742 705 100.0 0.16 (0.09, 0.23) otal events 226 104 eterogeneity: Tau ² = 0.01; Chi ² = 54.99, df = 17 ($P < 0.00001$); I ² = 69% est for overall effect: $Z = 4.66$ ($P < 0.00001$) est for subgroup difference: Chi ² = 8.66, df = 6 ($P = 0.19$); I ² = 30.7%									
IQahtani et al. ³⁴ (2018) 10 40 1 40 6.2 0.23 (0.08, 0.37) ubtotal (95% CI) 81 84 11.9 0.17 (0.06, 0.29) otal events 20 7 eterogeneity: Tau ² = 0.00; Chi ² = 1.14, df = 1 (P = 0.29); I ² = 13% est for overall effect: Z = 2.94 (P = 0.003) otal events 226 otal events 226 eterogeneity: Tau ² = 0.01; Chi ² = 54.99, df = 17 (P < 0.00001); I ² = 69% est for overall effect: Z = 4.66 (P < 0.00001)	1.1.7 TNF					_			
Abtotal (95% CI) 81 84 11.9 0.17 (0.06, 0.29) bala cvents 20 7 eterogeneity: Tau ² = 0.00; Chi ² = 1.14, df = 1 ($P = 0.29$); I ² = 13% est for overall effect: Z = 2.94 ($P = 0.003$) bala (95% CI) 742 705 100.0 0.16 (0.09, 0.23) bala (95% CI) 742 705 100.0 0.16 (0.09, 0.23) bala events 226 104 -1 -0.5 0 0.5 eterogeneity: Tau ² = 0.01; Chi ² = 54.99, df = 17 ($P < 0.00001$); I ² = 69% -1 -0.5 0 0.5 set for overall effect: Z = 4.66 ($P < 0.00001$) set for subgroup difference: Chi ² = 8.66, df = 6 ($P = 0.19$); I ² = 30.7% Non-smokers waterpipe									
ball events 20 7 eterogeneity: Tau ² = 0.00; Chi ² = 1.14, df = 1 (P = 0.29); I ² = 13% est for overall effect: Z = 2.94 (P = 0.003) ball (95% CI) 742 705 100.0 0.16 (0.09, 0.23) ball events 226 104 eterogeneity: Tau ² = 0.01; Chi ² = 54.99, df = 17 (P < 0.00001); I ² = 69% est for overall effect: Z = 4.66 (P < 0.00001) est for subgroup difference: Chi ² = 8.66, df = 6 (P = 0.19); I ² = 30.7% -1 -0.5 0 0.5 Non-smokers waterpipe	AlQahtani <i>et al.</i> ³⁴ (2018)	10		1					
eterogeneity: Tau ² = 0.00; Chi ² = 1.14, df = 1 ($P = 0.29$); I ² = 13% est for overall effect: $Z = 2.94$ ($P = 0.003$) btal (95% CI) 742 705 100.0 0.16 (0.09, 0.23) btal events 226 104 eterogeneity: Tau ² = 0.01; Chi ² = 54.99, df = 17 ($P < 0.00001$); I ² = 69% est for overall effect: $Z = 4.66$ ($P < 0.00001$) est for subgroup difference: Chi ² = 8.66, df = 6 ($P = 0.19$); I ² = 30.7%	Subtotal (95% CI)	20	81	_	84	11.9	0.17 (0.06, 0.29)	-	
est for overall effect: $Z = 2.94$ ($P = 0.003$) D tal (95% CI) 742 705 100.0 0.16 (0.09, 0.23) D tal events 226 104 eterogeneity: Tau ² = 0.01; Chi ² = 54.99, df = 17 ($P < 0.00001$); I ² = 69% est for overall effect: $Z = 4.66$ ($P < 0.00001$) P = 30.7% -1 -0.5 0 0.5 Non-smokers waterpipe			ת) 1		120/				
bala events 226 104 eterogeneity: Tau ² = 0.01; Chi ² = 54.99, df = 17 ($P < 0.00001$); I ² = 69% -1 -0.5 0 0.5 est for subgroup difference: Chi ² = 8.66, df = 6 ($P = 0.19$); I ² = 30.7% Non-smokers waterpipe			- 1 (1' =	0.27); 1~ =	13/0				
bala events 226 104 eterogeneity: Tau ² = 0.01; Chi ² = 54.99, df = 17 ($P < 0.00001$); I ² = 69% -1 -0.5 0 0.5 est for subgroup difference: Chi ² = 8.66, df = 6 ($P = 0.19$); I ² = 30.7% Non-smokers waterpipe	Fotal (95% CI)		742		705	100.0	0.16 (0.09, 0.23)	•	
eterogeneity: Tau ² = 0.01; Chi ² = 54.99, df = 17 (P < 0.00001); I ² = 69% -1 -0.5 0 0.5 est for subgroup difference: Chi ² = 8.66, df = 6 (P = 0.19); I ² = 30.7% Non-smokers waterpipe	Fotal events	226	/ 14	104	703	100.0	0.10 (0.07, 0.23)	•	
est for overall effect: $Z = 4.66 (P < 0.00001)$ est for subgroup difference: Chi ² = 8.66, df = 6 (P = 0.19); I ² = 30.7% Non-smokers waterpipe			f = 17 (P); I ² = 69 ⁶	%			
est for subgroup difference: $Chi^2 = 8.66$, $df = 6$ ($P = 0.19$); $I^2 = 30.7\%$ Non-smokers waterpipe					,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,				
			·	= 0.19); I ²	= 30.7%			Non-smokers waterpipe	
gure 2: Forest plot generated through RevMan 5.4.	0 1								

use. $^{\rm 48,49}$ This alteration could lead to apoptosis as well as the suppression of the cell cycle, senescence, differentiation and DNA repair. $^{\rm 48}$

Furthermore, a meta-analysis was carried out using RevMan 5.4 (Cochrane.org, London, UK). Indeed, a forest plot could only be created with RevMan




Figure 3: Risk of bias graph generated through RevMan 5.4.

in accordance with the different levels of variation regarding the aims and methods of the selected studies. This was because the included articles used different cells to assess cytotoxicity and genotoxicity in different ways [Figure 2]. Of the 20 articles included, nine rated genotoxicity while 11 rated cytotoxicity. As per evidence from the literature, waterpipe smoke was believed to have several cytotoxic and genotoxic effects on oral cells, with a risk difference of 0.16 (95% CI: 0.09–0.23; P <0.00001).

A graph depicting the risk of bias was created by RevMan 5.4 using the QUADAS-2 protocol [Figure 3]. Indeed, the high quality of the study articles can be observed in this graph. The articles came from all over the world, mainly from the Middle East (n = 14); out of the two multicentre studies, two were conducted in Africa and the other two came from Europe and South America, respectively.^{4,8,32,42,44,49} The predominance of studies from the Middle East can be explained by the higher and more frequent consumption of waterpipe in the region.

Discussion

Although waterpipe use is a worldwide phenomenon, several included studies noted an urgent concern with waterpipe smoking in Middle Eastern countries, where it is widespread.^{32,40,48}

Such concern is appreciable, as waterpipe smoke condensate reportedly revealed many organic compounds that are well-known for their genotoxic and carcinogenic properties-such as nicotine, tar, heavy metals, polycyclic aromatic hydrocarbons (naphthalene, phenanthrene, fluoranthene), aldehydes (5-hydroxymethyl-5-furancarboxaldehyde, 3-ethoxy-4-hydroxybenzaldehyde) and also carbon monoxide.33,40,43 In the included studies, the volume of formaldehyde detected in waterpipe smoke was five times higher than its volume in one 2R4F cigarette (a 2R4F cigarette is a standard reference cigarette; tobacco industries as well as academic laboratories use this reference cigarette to standardise test items and conduct inhalation toxicity research).33

Notably, in the selected studies, high values were found for all critical comet assay parameters

(a sensitive technique of DNA damage detection) in buccal cells, suggesting that waterpipe use comprises DNA-damaging ingredients.^{32,33,37,38,44} For example, DNA methylation due to waterpipe use could reach up to a 64% level;³⁷ this should be alarming, as samples with only 10% methylation are considered as significantly methylated.

An effective technique to evaluate the impact of environmental factors on genetic stability is the investigation of the micronuclei-the products of early events in human carcinogenic processes, especially in the oral cavity; they are considered biomarkers of genotoxicity.41 According to the included studies, total micronuclei (TMN) and cells with micronuclei (CMN) were significantly higher among waterpipe users (very similar to the same values for cigarettesmokers) compared to NS groups.^{8,41,49} Furthermore, there was no association between TMN and CMN regarding lifetime duration of use, time of first waterpipe smoke of the day and number of times per day/week.8 Waterpipe use was also related to chromosomal aberrations and an increased level of micronuclei.8,33,38-41

Moreover, in the waterpipe smoke mixtures, mutagenic and genotoxic contaminants were present at low levels; however their detection was challenging since a few components were in available high concentrations.33 In addition, genotoxicity was not related to a specific compound but to a set of properties and chemical interactions of the entire sample of one selected study.³³ In other words, waterpipe use was related to genomic and gene expression alterations, for both RNA and DNA.4,32,33,37,44

Furthermore, waterpipe use increased the risk of histopathologic changes including acanthosis, epithelial dysplasia, hyperparakeratosis and the development of abnormal rete ridges.⁴⁶ Acanthosis and epithelial dysplasia in WS were also similar to those of cigarette smokers (CS).46 In addition, cytomorphometric quantitative analysis showed higher values for WS groups than NS groups concerning nuclear and cell perimeter, cytoplasm size, cell area, nuclear-cytoplasmic ratio and the big diameter of nucleus/small diameter of nucleus ratio, besides the induction of heterochromatinisation in cell nuclei,

a situation caused by different stress factors.^{42,44,45} Additionally, some studies observed increases in multinucleated cells, pyknosis, karyorrhexis, karyolysis in WS groups compared to NS groups, the former groups' values being slightly higher than those of the CS groups.^{38,39,43–45} There was also a higher incidence of cytoplasm vacuolisation concerning NS as well as CS groups.⁴⁵ Malignant and pre-malignant lesions were found to facilitate an increase in the nuclear-cytoplasmic ratio.

Pro-inflammatory cytokine levels (interleukin-1 β , interleukin-6, interleukin-3, and tumour necrosis factor- α) were statistically found to be higher among WS groups compared to NS, a result similar to other kinds of tobacco users, such as CS, E-cigarettes, and cigars.^{32,34–36} Additionally, cell necrosis and apoptosis were found to be closely related to carcinomas.

Protein p53 expression was found to have a relation to the regulation of apoptosis and genomic stability, along with playing a crucial role in tumour suppression (it was named the 'guardian of the genome'). WS groups had a significantly higher p53 mutation than NS groups in samples with malignant, pre-malignant, or even normal oral epithelium.^{48,49} This correlation was similar to that of the CS groups.⁴⁹ In addition, the repair index of the oral mucosa cells of WS groups was significantly lower than that of the NS groups.³⁹ Evidently, the cytotoxic effects of waterpipe smoke were more correlated to time exposure than those of cigarette smoke.^{41,43,44,50}

However, there was no peak incidence of oral cancer in WS groups regarding age or gender.^{43,47} Although a few papers included female samples due to oral mucosa alterations concerning hormonal changes, waterpipe use was found to be much more common in males than females.^{45,46}

Furthermore, waterpipe and cigarette users demonstrated similar effects on oral mucosa, including a substantial increase of association with oral squamous cell carcinoma (OSCC) development.37,42,43,46-49 The combination of waterpipe and shammah (Arabian snuff) or waterpipe and cigarettes led to a higher incidence of oral cancer compared to only one kind of tobacco use.47,49 In fact, the use of waterpipe was found to have more unfavourable effects than cigarette smoking.38,42 On the other hand, the combined use of waterpipe and shammah increased the risk of developing OSCC by nearly 35 times.⁴⁷ Khat chewing did not demonstrate any significant impact on the development of oral cancer.⁴⁷ However, when associated with waterpipe use, it lead to an increased risk of oral cancer.46

In this light and in addition to more restrictive legislation and interventional policy aspects, tobacco

cessation programmes must become a priority in some concomitantly affected regions. These programmes can consist of education, psychological therapy and pharmacological aid, especially for young people who believe that waterpipe smoking is a safe addiction.^{40,44,47,48}

Conclusions

Waterpipe use has genotoxic and cytotoxic effects on human oral cells, with a risk difference of 0.16 (P <0.05). It seems to increase the incidence of oral cancer, contrary to popular belief. Furthermore, its carcinogenicity is similar to that of cigarette smoke.

AUTHORS' CONTRIBUTIONS

RG was involved in conceptualisation, design, data collection, data analysis and the drafting of the manuscript. MK and YSS contributed to the design, data collection, data analysis and the drafting of the manuscript. All authors approved the final version of the manuscript.

References

- Jawad M, Charide R, Waziry R, Darzi A, Ballout RA, Akl EA. The prevalence and trends of waterpipe tobacco smoking: A systematic review. PLoS One 2018; 13:e0192191. https://doi. org/10.1371/journal.pone.0192191.
- Bou Fakhreddine HM, Kanj AN, Kanj NA. The growing epidemic of water pipe smoking: Health effects and future needs. Respir Med 2014; 108:1241–53. https://doi. org/10.1016/j.rmed.2014.07.014.
- Souza ACF, Galvani MG, de Souza DV, Ribeiro DA. Cytogenetic biomonitoring on oral mucosa cells of Hookah users: Is it possible? Asian Pac J Cancer Prev 2020; 21:1849. https://doi. org/10.31557/APJCP.2020.21.7.1849.
- Patil S, Patel K, Advani J, Subbannayya T, Rajagopalan P, Babu N, et al. Multiomic analysis of oral keratinocytes chronically exposed to shisha. J Oral Pathol Med 2019; 48:284–9. https:// doi.org/10.1111/jop.12828.
- Walters MS, Salit J, Ju JH, Staudt MR, Kaner RJ, Rogalski AM, et al. Waterpipe smoking induces epigenetic changes in the small airway epithelium. PLoS One 2017; 12:e0171112. https://doi. org/10.1371/journal.pone.0171112.
- Ringh MV, Hagemann-Jensen M, Needhamsen M, Kular L, Breeze CE, Sjöholm LK, et al. Tobacco smoking induces changes in true DNA methylation, hydroxymethylation and gene expression in bronchoalveolar lavage cells. EBioMedicine 2019; 46:290–304. https://doi.org/10.1016/j.ebiom.2019.07.006.
- Szyf M, Pakneshan P, Rabbani SA. DNA methylation and breast cancer. Biochem Pharmacol 2004; 68:1187–97. https://doi. org/10.1016/j.bcp.2004.04.030.
- El-Setouhy M, Loffredo CA, Radwan G, Rahman RA, Mahfouz E, Israel E, et al. Genotoxic effects of waterpipe smoking on the buccal mucosa cells. Mutat Res Genet Toxicol Environ Mutagen 2008; 695:36–40. https://doi.org/10.1016/j. mrgentox.2008.06.014.
- Kamboj M, Mahajan S. Micronucleus An upcoming marker of genotoxic damage. Clin Oral Investig 2007; 11:121–6. https:// doi.org/10.1007/s00784-006-0075-y.

- Maziak W. The waterpipe: An emerging global risk for cancer. Cancer Epidemiol 2013; 37:1–4. https://doi.org/10.1016/j. canep.2012.10.013.
- Mulrow CD. Rationale for systematic reviews. BMJ 1994; 309:597-9. https://doi.org/10.1136/bmj.309.6954.597.
- Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 2009; 6:e10000097. https://doi.org/10.1371/journal.pmed.1000097.
- Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. Quadas-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011; 155:529–36. https://doi.org/10.7326/0003-4819-155-8-201110180-00009.
- Patil S, Babu N, Subbannayya T, Mohan SV, Sathe G, Solanki HS, et al. Secretome analysis of oral keratinocytes chronically exposed to shisha. Cancer Biomarkers 2019; 25:29–41. https:// doi.org/10.3233/CBM-182099.
- Patil S, Rajagopalan P, Patel K, Subbannayya T, Babu N, Mohan SV, et al. Chronic shisha exposure alters phosphoproteome of oral keratinocytes. J Cell Commun Signal 2019; 13:281–9. https://doi.org/10.1007/s12079-019-00528-4.
- Patil S, Subbannayya T, Mohan SV, Babu N, Advani J, Sathe G, et al. Proteomic changes in oral keratinocytes chronically exposed to Shisha (water pipe). OMICS 2019; 23:86–97. https://doi.org/10.1089/omi.2018.0173.
- Dehghannezhad M, Jalayer Naderi N, Semyari H, Naderi NJ, Semyari H. Micronucleus assay of buccal mucosa cells in waterpipe (hookah) smokers: A cytologic study. Iran J Pathol 2020; 15:75–80. https://doi.org/10.30699/ijp.2020.101701.2010.
- Ibraheem WI, Fageeh HI, Preethanath RS, Alzahrani FA, Al-Zawawi AS, Divakar DD, et al. Comparison of RANKL and osteoprotegerin levels in the gingival crevicular fluid of young cigarette- and waterpipe-smokers and individuals using electronic nicotine delivery systems. Arch Oral Biol 2020; 115:104714. https://doi.org/10.1016/j.archoralbio.2020.104714.
- Patil S, Awan KH, Arakeri G, Aljabab A, Ferrari M, Gomes CC, et al. The relationship of "shisha" (water pipe) smoking to the risk of head and neck cancer. J Oral Pathol Med 2019; 48:278– 83. https://doi.org/10.1111/jop.12823.
- Chaouachi K. Micronuclei and shisha/goza smoking in Egypt. Mutat Res Genet Toxicol Environ Mutagen 2009; 675:81–2. https://doi.org/10.3390/ijerph6020798.
- Yakin M, Gavidi RO, Cox B, Rich A. Oral cancer risk factors in New Zealand. N Z Med J 2017; 130:30–8.
- Dar NA. Narghile smoking is associated with the development of oral cancer at early age. J Evid Based Dent Pract 2015; 15:126–7. https://doi.org/10.1016/j.jebdp.2015.07.001.
- Warnakulasuriya S. Waterpipe smoking, oral cancer and other oral health effects. Evid Based Dent 2011; 12:44–5. https://doi. org/10.1038/sj.ebd.6400790.
- Albeitawi S, Hamadneh J, Al-Shatanawi TN, Al Mehaisen L, Al-Zubi M. Effect of hookah (water pipe) smoking on semen parameters. Andrologia 2020; 52:e13723. https://doi. org/10.1111/and.13723.
- Chaouachi K, Sajid KM. A critique of recent hypotheses on oral (and lung) cancer induced by water pipe (hookah, shisha, narghile) tobacco smoking. Med Hypotheses 2010; 74:843–6. https://doi.org/10.1016/j.mehy.2009.11.036.
- Rastam S, Li FM, Fouad FM, Kamal HMA, Akil N, Al Moustafa AE. Water pipe smoking and human oral cancers. Med Hypotheses 2010; 74:457–9. https://doi.org/10.1016/j. mehy.2009.10.013.
- Shakhatreh MAK, Khabour OF, Alzoubi KH, Masadeh MM, Hussein EI, Bshara GN. Alterations in oral microbial flora induced by waterpipe tobacco smoking. Int J Gen Med 2018; 11:47–54. https://doi.org/10.2147/IJGM.S150553.

- Vallès Y, Inman CK, Peters BA, Ali R, Wareth LA, Abdulle A, et al. Types of tobacco consumption and the oral microbiome in the United Arab Emirates Healthy Future (UAEHFS) Pilot Study. Sci Rep 2018; 8:11327. https://doi.org/10.1038/s41598-018-29730-x.
- Nemmar A, Al-Salam S, Beegam S, Yuvaraju P, Oulhaj A, Ali BH. Water-pipe smoke exposure-induced circulatory disturbances in mice, and the influence of betaine supplementation thereon. Cell Physiol Biochem 2017; 41:1098–112. https://doi. org/10.1159/000464117.
- Imran S, Shan M, Muazam S. A comparative histological study of submucosal gland hypertrophy in trachea of mice exposed to cigarette and shisha smoke. J Coll Physicians Surg Pak 2018; 28:192–5. https://doi.org/10.29271/jcpsp.2018.03.192.
- Babu N, Patil S, Mohan SV, Subbannayya T, Advani J, Datta KK, et al. Signaling alterations in oral keratinocytes in response to shisha and crude tobacco extract. J Oral Pathol Med 2020; 50:459–69. https://doi.org/10.1111/jop.13154.
- López-Ozuna VM, Gupta I, Kiow RLC, Matanes E, Kheraldine H, Yasmeen A, et al. Water-pipe smoking exposure deregulates a set of genes associated with human head and neck cancer development and prognosis. Toxics 2020; 8:73. https://doi. org/10.3390/toxics8030073.
- Al-Amrah HJA, Aboznada OA, Alam MZ, Elassouli MZM, Mujallid MI, Elassouli SM. Genotoxicity of waterpipe smoke in buccal cells and peripheral blood leukocytes as determined by comet assay. Inhal Toxicol 2014; 26:891–6. https://doi.org/10.3 109/08958378.2014.970787.
- AlQahtani MA, Alayad AS, Alshihri A, Correa FOB, Akram Z. Clinical peri-implant parameters and inflammatory cytokine profile among smokers of cigarette, e-cigarette, and waterpipe. Clin Implant Dent Relat Res 2018; 20:1016–21. https://doi. org/10.1111/cid.12664.
- 35. Abduljabbar T, Akram Z, Vohra F, Warnakulasuriya S, Javed F. Assessment of interleukin-1β, interleukin-6, and tumor necrosis factor-A levels in the peri-implant sulcular fluid among waterpipe (narghile) smokers and never-smokers with peri-implantitis. Clin Implant Dent Relat Res 2018; 20:144–50. https://doi.org/10.1111/cid.12557.
- 36. Mokeem SA, Alasqah MN, Michelogiannakis D, Al-Kheraif AA, Romanos GE, Javed F. Clinical and radiographic periodontal status and whole salivary cotinine, IL-1β and IL-6 levels in cigarette- and waterpipe-smokers and E-cig users. Environ Toxicol Pharmacol 2018; 61:38–43. https://doi.org/10.1016/j. etap.2018.05.016.
- Sabi SH, Khabour OF, Alzoubi KH, Cobb CO, Eissenberg T. Changes at global and site-specific DNA methylation of MLH1 gene promoter induced by waterpipe smoking in blood lymphocytes and oral epithelial cells. Inhal Toxicol 2020; 32:124–30. https://doi.org/10.1080/08958378.2020.1754972.
- Rajabi-Moghaddam M, Haji Mirzamohammad M, Yahyazadeh E, Gholinia H, Abbaszadeh H. Comparison of genotoxic effect in buccal exfoliated cells between cigarette and waterpipe smokers. Acta Cytol 2020; 64:471–6. https://doi. org/10.1159/000506893.
- Taghibakhsh M, Farhadi S, Babaee A, Sheikhi M. The effect of hookah use on buccal mucosa: Evaluation of repair index. Asian Pac J Cancer Prev 2019; 20:1109–12. https://doi.org/10.31557/ APJCP.2019.20.4.1109.
- Eker ED, Koyuncu H, Şahin NÖ, Yüksel A, Berköz M, Diler SB, et al. Determination of genotoxic effects of hookah smoking by micronucleus and chromosome aberration methods. Med Sci Monit 2016; 22:4490–4. https://doi.org/10.12659/msm.898593.
- Prasad P, Hamed MS, Nahar P. Micronucleus assay in waterpipe tobacco and cigarette smokers: A comparative study. J Contem Dent Pract 2019; 20:101–7. https://doi.org/10.5005/jpjournals-10024-2483.

- Volkova O, Ryabokon E, Magda I, Shckorbatov Y. Impact of smoking habits on the state of chromatin and morphology of buccal epithelial cells among medical students. Georgian Med News 2017; 111–15.
- Naderi NJ, Pasha MP. Comparison of cytotoxic effect of cigarette and waterpipe smoking on human buccal mucosa. Int J Prev Med 2017; 8:98. https://doi.org/10.4103/ijpvm. IJPVM_62_17.
- Silveira MAD, Antonelli AS, Fiorelli BO, D'Arce LPG. Cytological multimarker screening using BMCyt test in waterpipe smokers: An integrative study of cell damage, toxicological and cancer risk. J Genet 2018; 97:399–404.
- Seifi S, Feizi F, Mehdizadeh M, Khafri S, Ahmadi B. Evaluation of cytological alterations of oral mucosa in smokers and waterpipe users. Cell J 2014; 15:302–9.
- 46. Ali AA. Histopathologic changes in oral mucosa of Yemenis addicted to water-pipe and cigarette smoking in addition to takhzeen al-qat. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 103:e55–9. https://doi.org/10.1016/j. tripleo.2006.10.008.

- Alharbi F, Quadri MFA. Individual and integrated effects of potential risk factors for oral squamous cell carcinoma: A hospital-based case- control study in Jazan, Saudi Arabia. Asian Pac J Cancer Prev 2018; 19:791–6. https://doi.org/10.22034/ APJCP.2018.19.3.791.
- Zaid K, Azar-Maalouf E, Barakat C, Chantiri M. p53 Overexpression in oral mucosa in relation to Shisha smoking in Syria and Lebanon. Asian Pac J Cancer Prev 2018; 19:1879–82. https://doi.org/10.22034/APJCP.2018.19.7.1879.
- Amer HW, Waguih HM, El-Rouby DH. Development of field cancerization in the clinically normal oral mucosa of shisha smokers. Int J Dent Hyg 2019; 17:39–45. https://doi. org/10.1111/idh.12362.
- WHO Study Group on Tobacco Product Regulation (TobReg). Waterpipe tobacco smoking: Health effects, research needs and recommended actions for regulators. Geneva: World Health Organization. 2015.